This post will teach you how to win a cannabis business license in any state, regardless of the license type. Competition for cannabis licenses is often fierce, and license limitations and complexities of the application process can be daunting enough to deter even extremely savvy business owners, making the chances of winning a cannabis license frustratingly low – unless you’re an MSO. With this guide, we have simplified the entire process into ten easy to understand steps to win a cannabis business license, and provide thorough details and instructions that are often tightly held secrets among consultants and attorneys.
DISCLAIMER: This article details the process of developing and applying for a cannabis business license – it does not discuss how to start or run a business. This publication assumes the applicant comes to the table with a business plan, funding, and team in place.
Step 1: Read the Statutes
Statutes tend to be the highest and/or first level of law, from which regulations are often developed. Statutes typically define the duties of the State in carrying out cannabis legalization and licensing efforts. However, these laws are often nothing more than a general guideline, whereas the Regulations developed from said Statues tend to be much more descriptive, thorough, and complex.
Tips for Statutes Reading:
Read ALL of the Statutes, including Definitions. For instance, applicants often have questions where the answer is not apparent in the body of the Statutes, however, the Definitions sometimes describe terms in a way that clarify items of uncertainty.
Don’t skim: at least one person on your team should carefully read every passage in the Statutes.
Sometimes statutes are forgotten or ignored when Regulations are created, so it’s important to cross-reference any sections or passages that are confusing or seem to be omitted from the Regulations.
Make a searchable Statutes document: often states don’t publish Statutes in a way that is easy to track and understand. The best solution for this problem is to copy and paste all of the Statutes into a running Word document. Then, you can use Control+F to search the compiled Word document for any term you are seeking information about – this is particularly useful when crafting license application narratives: see more in Step 7 below.
Make a critical list: for any passages that are extremely relevant to your cannabis license application, make a list of these critical items, ideally in a spreadsheet. For instance, Statutes that refer to odor mitigation is critical for cultivators, while Statutes that refer to dealing with the public are especially important for dispensaries.
Step 2: Read the Regulations
Regulations detail the bulk of the rules related to applying for a cannabis business license. However, it should be noted that a significant amount of time can elapse between the creation of Statutes, and the subsequent development and publishing of Regulations. Cannabis license applicants should plan accordingly.
When Regulations are released, these should be painstakingly read in their entirety, ideally multiple times by every executive on your team. Your Chief Compliance Officer and your attorney should become intensively familiar with these laws. The process for reviewing Regulations is similar to that for Statutes, as detailed below.
Tips for Regulations Reading:
Read ALL of the Regulations in their entirety
Cross reference Regulations with Statutes
Make a searchable Regulations Word document
Make a list of passages that are critical to your license type
Make a list of passages that don’t make sense, passages that conflict with other sections of the Regulations or Statutes, and missing citations. This list can be used to query the State or the State’s cannabis regulatory body for clarification. For this purpose, consider hiring a lobbyist with access to the regulatory body.
Step 3: Read the RFA/Notice of Acceptance
When a state is finally ready to start accepting cannabis business license applications, a Request for Applications (“RFA”), Final Notice, or other document is released that provides details on what the state wants submitted as part of the cannabis license application process. Unlike Statutes and Regulations, which discuss the process of laws, an RFA or Final Notice primarily discusses precisely how a cannabis business will submit an application, and how they will carry out some of the processes of their license type, as well as the general requirements of individuals named in the application, and of the application entity.
The steps for reviewing an RFA or Final Notice are similar to those for Regulations and Statutes.
Tips for RFA reading:
Read ALL of the RFA/Final Notice in its entirety
Cross reference with Regulations and Statutes
Make a searchable RFA/Final Notice Word document
Make a list of RFA passages that are critical to your license type
Make a list of RFA passages that don’t make sense, passages that conflict with other sections of the Regulations or Statutes, and missing citations. Address these issues with the state cannabis regulatory body.
Step 4: Read the Ordinances
Ordinances dictate requirements for cannabis business license applicants at a local or municipal level. Sometimes, municipalities will require a separate cannabis license application for the town or city in question, while in other cases the state level application is sufficient. Ordinances will generally differ from Statutes, Regulations, and the RFA in that they describe what one must do locally to win a cannabis business license. These local requirements often center around zoning issues, distance setback requirements, parking lot and access controls, security, waste disposal, and other local issues. The process for reviewing Ordinances is similar to the process for reviewing Statutes, Regulations, and the RFA.
Tips for Ordinances reading:
Read ALL of the Ordinances in their entirety
Cross reference with Regulations, Statutes, and the RFA/Final Notice
Make a searchable Ordinances Word document
Make a list of Ordinance passages that are critical to your license type
Make a list of Ordinance passages that don’t make sense, passages that conflict with other sections of the Regulations, Statutes, or RFA, and missing citations. Address these issues with the municipality directly.
Step 5: Prepare a List of Required Documents and Information
Use the RFA/Final Notice and Ordinances to generate a list of documents needed for the cannabis license application. These documents can include formation and tax documents, insurance documents, business and personal records, certifications and licenses, manuals, plans, SOPs, waivers, affidavits, disclaimers, resumes, background checks and criminal history reports, floor plans, architectural designs, security overlays, minority and diversity statuses, resumes, personal identification, and other types of documents required for the application process.
Ensure that your entire team is comfortable providing all of the required information, including items that can be extremely personally invasive, such as background checks, fingerprints, taxes, personal history disclosure forms, and other sensitive details. Reluctance or refusal to provide these details can delay a cannabis license application significantly, or disqualify it in some cases.
Step 6: Write the Plans, Narratives, and/or SOPs
The heavy work of winning a cannabis license is in the writing of narratives and plans required by the state regulatory body. After you have generated a list per Step #5 above, assign these plans and documents to your executive team, attorneys, consultants, managers, employees, vendors or contractors, and other relevant individuals and organizations.
When writing plans for a cannabis license application, speak to the state regulatory body in their own language, using appropriate citations whenever possible. Remember that the hierarchy of citations is Statutes, Regulations, RFA/Final Notice, and finally, Ordinances. The following is the general concept for this type of writing, using a Waste Disposal Plan as an example (which is required by nearly every state cannabis licensing authority):
Review all requirements in the Statutes, Regulations, Final Notice, and Ordinances related to waste disposal. This is where the Word documents you created in previous steps will be useful – you can use Control+f to search each document for instances of “waste disposal” and similar terms, to be sure you locate and understand precisely what the state wants in regard to this issue.
After reviewing all of the information available related to waste disposal, craft a narrative that tells the state regulatory body that you not only understand all of the requirements, but also impart details on exactly how your cannabis business will carry out the steps necessary to ensure compliance with the state’s waste disposal requirements. For instance, “We will install cameras in restricted areas where cannabis and cannabis products are slated to be destroyed, and we will record and store all activities related to the destruction and disposal of cannabis products.”INSERT CITATION HERE. <<<<This citation will be the Statute, Regulation, or other legal citation that lists the exact section and subsection of where the state’s requirement regarding recording of waste disposal activities can be found.
Because state documents are often written in chronological or other order, you can craft narratives and plans to address each of the state’s requirements in the same order. However, always use original writing: do not copy-paste or closely mirror what the state or other authority has written. For instance, Regulations regarding waste disposal may be written in the following order:
Identifying cannabis and cannabis products to be disposed of
Quarantining and sequestration of cannabis products slated for disposal
Destruction of the cannabis products
Recording of the waste disposal process and related record-keeping
In fact, it’s often easiest to use the state’s requirements as an outline for your plan.
Tips for writing narratives, SOPs, plans, and other documents:
Write in active voice
Use persuasive narrative style
Include relevant citations whenever possible
Use Times New Roman at 11- or 12-point font
Write factually
Refer to chemovars and phytochemical content
Write directly to the state prompt
Step 7: License Materials Editing
All of the documents created for the cannabis license application must be edited. Editing processes are often collaborative, and in general no writer should ever be permitted to edit their own work as the final editor. Therefore, if, for instance, your company’s CCO writes the required Regulatory Compliance Plan, another executive, attorney, or consultant should edit the plan. Multi-level editing is preferred, but at the minimum, each document will have one writer and one editor. Editing should occur on 3 basic levels:
Editing for grammar, spelling, content, voice, syntax, etc.
Editing for accuracy of information provided
Editing for citations – ensuring that the citation listed is from the appropriate section of the regulatory body document
Step 8: Cannabis Application Materials Compilation and Redactions
All of the documents described above must be compiled in the manner prescribed by the state or regulatory body. This is generally described in the RFA or Final Notice. In some cases, paper copies must be bound in a certain order and mailed or delivered by hand, while other states have asked for the delivery of materials on thumb or zip drives. Recently, state website portals have opened to allow submission of application materials electronically, which significantly simplifies the compilation and submission process.
Often, information contained in the narratives, plans, and other documents submitted as part of the cannabis business license application are required by law to be redacted. Redactions are generally related to privacy laws, which is often a local issue where counsel familiar with the state or municipal requirements for redactions should be employed.
Step 9: Submission of Application
After completing all of the above steps, the application must be submitted in the prescribed manner in the timeline offered – pay careful attention to this. For instance, if you submit your cannabis license application early – before the opening date for acceptance – some states will automatically disqualify your application. However, while submitting before a hard deadline is of key concern, submitting in the timeline provided by the state isn’t always so concise: some states have rolling applications with no deadline, some have a single day where applications are due, and some have short windows of time – often a month or less – where applications are accepted.
While submitting by any required deadline or timeline is critical, ensuring that all application materials are complete is just as important. If you rush to the deadline or submission date and miss a document, or submit an application that is even slightly incomplete, it will most likely be rejected.
PRO tip:
If the state application submission process asks for information or documents that don’t apply to your cannabis business, don’t do nothing. Instead, write and submit a document that describes why the request doesn’t apply.
Step 10: Correction and Rejections for Cure
Even if you follow the previous nine steps to the letter, there is still a small chance that the state regulatory body could reject your application. In many cases this could be a temporary rejection where what’s called a ‘cure’ is required. This cure could be something as simple as a forgotten or lost minor document, or something as complex as additional financial source details. Whatever the cure request is, you must take action immediately and provide the required information, and then resubmit the application as quickly as possible.
Conclusion
State cannabis regulatory bodies often make the process to obtain a cannabis license arduous, expensive, and complicated – even in states with social equity cannabis licenses. However, if you follow these 10 steps to win a cannabis license, your chances will significantly improve. And with right help and the right team behind your application, you can win: even multiple licenses, in multiple states and countries.
This comprehensive guide to 280E for cannabis businesses in the United States is designed to assist industry stakeholders in complying with the tax laws while also maximizing any possible deductions or exemptions. Herein we exhaustively detail the history, impact, and future of US tax code 280E, and how cannabis businesses can reasonably maintain compliance with these seemingly heavy-handed laws.
280E consists of three simple lines of tax code that have created a significant and sometimes fatal burden for regulated cannabis businesses nationwide:
“No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business consists of trafficking in controlled substances which is prohibited by Federal law or the law of any State in which such trade or business is conducted.”
Enacted in September of 1982 with the intention to curtail illegal drug trafficking, section 280E from Title 26 of the Internal Revenue Code denies all standard business credits and deductions for licensed cannabis operators. This includes ordinary business expenses such as rent, facility maintenance, advertising, and employee insurance premiums. Usually, these deductions lower the taxable income of a business, resulting in less overall federal tax liability. Cannabis businesses are instead taxed on the entirety of their income without the offset of operational expenditures, creating profitability issues throughout the industry.
History of 280E
Cannabis has been classified federally by the Drug Enforcement Administration (“DEA”) as a Schedule I drug[2] since drugs were first scheduled in 1970. Schedule I substances are defined by three characteristics[3]: a high potential for abuse, a lack of accepted safety for use of the drug under medical supervision, and no currently accepted medical use for treatment in the United States. This categorization is meant to represent substances with the highest potential for abuse. Other Schedule I drugs include heroin, LSD, ecstasy, and peyote. Isomers or other pharmacologically similar derivatives of Schedule I drugs intended for human consumption[4] are considered to be Schedule I drugs as well. Interestingly, the National Commission on Drug Abuse created by Richard Nixon recommended the decriminalization of cannabis in 1972, stating that the drug does not present a potential danger to public safety; however, this advice was not taken, and cannabis remains a Schedule I substance over 50 years later.
The IRS has long maintained that all income is taxable and should be reported, regardless of whether the income was legally obtained or not[5],[6],[7]. In 1974, a self-employed cocaine and cannabis dealer in Minnesota by the name of Jeffrey Edmondson abided by these guidelines and filed an income tax return showing his gross revenue, cost of goods sold, and standard business deductions. His business deductions included packaging expenses, a small measuring scale, telephone expenses, and automobile expenses such as maintenance and mileage. The Tax Commissioner responded with a deficiency notice that found reason to disallow all business expenses, including costs of goods sold. The resulting court case, Edmondson v Commissioner, determined in 1981 that despite the illegality of actions and subsequent conviction of Edmondson related to drug trafficking, all of his necessary business tax deductions should be allowed[8]. Due to inconsistencies in Edmondson’s inventory tracking, calculated costs of goods sold were disallowed as deductions in the final verdict. Less than a year later Section 280E was added to the tax code, applicable to all businesses associated with trafficking Schedule I and II substances. The Senate Finance Committee report[9] at the time provided the following statement as justification:
“Ordinary and necessary trade or business expenses are generally deductible in computing taxable income. A recent US Tax Court case allowed deductions for telephone, auto, and rental expenses incurred in the illegal drug trade. In that case, the Internal Revenue Service challenged the amount of the taxpayer’s deduction for the cost of goods (illegal drugs) sold, but did not challenge the principle that such amounts were deductible.
On public policy grounds, the Code makes certain otherwise ordinary and necessary expenses incurred in a trade or business nondeductible in computing taxable income. These nondeductible expenses include fines, illegal bribes and kickbacks, and certain other illegal payments.
There is a sharply defined public policy against drug dealing. To allow drug dealers the benefit of business expense deductions at the same time that the U.S. and its citizens are losing billions of dollars per year to such persons is not compelled by the fact that such deductions are allowed to other, legal, enterprises. Such deductions must be disallowed on public policy grounds.”
Congress and the Congressional Research Service maintain that the use of ‘or’ in Section 280E extends the statute to situations in which federal law prohibits the conduct even if state law allows it[10]. The Tax Court has defined “trafficking” to mean “to engage in commercial activity: buy and sell regularly” and therefore the purchase and sale of cannabis constitutes trafficking even when permitted by state law. The Congressional Research Service and The Internal Revenue Service further maintain that criminal charges are not a necessary precursor to an audit[11] or investigation related to 280E.
280E Reform Efforts
Legislation has been filed at the federal level in each session for the last decade to improve the cannabis business environment in the US, with several examples listed here. Multiple bills have been introduced specifically to exempt state licensed cannabis businesses from the 280E restrictions.
2013 – Rep. Earl Blumenauer (D-OR) – H.R.2240 – “Small Business Tax Equity Act” looked to create an exception to IRC 280E that allows businesses operating in compliance with state laws to take business-related deductions associated with the sale of marijuana just like any other legal business[12],[13].
2015 – Sen. Ron Wyden (D-OR) – S.987 – “Small Business Tax Equity Act[14]” see above for description.
2017 – Rep. Carlos Curbelo (R-FL) – H.R.1810 – “Small Business Tax Equity Act” see above for description.
2017 – Sen. Cory Booker (D-NJ) – S.1689 – “Marijuana Justice Act” sought to remove marijuana and THC from Schedule I of the Controlled Substances Act and establish a Community Reinvestment Fund in the Treasury, with funds reinvested into communities most affected by the war on drugs[15].
2018 – Sen. Cory Gardner (R-CO) and Sen. Elizabeth Warren (D-MA) – S.3032 and Rep. David Joyce (R-OH) – H.R.6043 – “Strengthening the Tenth Amendment Through Entrusting States (STATES) Act” vowed to eliminate regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act for marijuana-related conduct and activities that are authorized by state or tribal law. It also expands banking options for cannabis businesses as a result[16].
2018 – Sen. Chuck Schumer (D-NY) – S.3174 – “Marijuana Freedom and Opportunity Act” aimed to remove marijuana from the list of scheduled substances, eliminate criminal penalties associated with import, export, and distribution, and require federal research on the impact of marijuana use on public health[17].
2019 – Sen. Kamala Harris (D-CA) – S.2227 and Rep. Jerrold Nadler (D-NY) – H.R.3884 -“Marijuana Opportunity Reinvestment and Expungement Act” commonly referred to as the MORE Act, this bill attempted to legalize marijuana at the federal level and allow state-legal cannabis businesses to deduct ordinary and necessary business expenses from their federal taxes[18].
2019 – Rep. Ed Perlmutter (D-CO) – H.R.1595 – “Secure and Fair Enforcement Act” commonly referred to as the SAFE Banking Act, would offer protections for banks that provide financial services to state-legal cannabis businesses[19]. While not directly related to 280E, this would have significantly reduced the financial burden currently facing cannabis operations.
2019 – Rep. Greg Steube (R-FL) – H.R.4323 – “Marijuana 1-to-3 Act” sought to change cannabis to a Schedule III substance given multiple currently accepted medical uses and low potential for abuse or dependence[20], which would have removed 280E implications for cannabis businesses.
2019 – Sen. Ron Wyden (D-OR) – S.420 and Rep. Earl Blumenauer (D-OR) – H.B.1120 – “Marijuana Revenue and Regulation Act” would have repealed Section 280E and established a federal regulatory framework for the taxation and regulation of the cannabis industry[21],[22].
2019 – Sen. Chuck Schumer (D-NY) – S.1552 – “Marijuana Freedom and Opportunity Act” see above for description.
2019 – Sen. Elizabeth Warren (D-MA) and Sen. Cory Gardner (R-CO) – S.1028 and Rep. Earl Blumenauer (D-OR) and David Joyce (R-OH) – “STATES Act” see above for description.
2019 – Rep. Earl Blumenauer (D-OR) – H.R.1118 and Sen. Ron Wyden (D-OR) – S.422 – “The Small Business Tax Equity Act” see above for description.
2021 – Rep. Jerrold Nadler (D-NY) – H.R.3617 -“MORE Act” see above for description.
2021 – Rep. Nancy Mace (R-SC) – H.R.597 – “STATES Act” see above for description.
2021 – Rep. Ed Perlmutter (D-CO) – H.R.1996 – “SAFE Banking Act” see above for description.
2021 – Rep. David Joyce (R-OH) – H.R.3105 – “Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act” sought to remove federal restrictions on marijuana-related activities that are authorized by state and tribal law, specifically removing cannabis from the list of scheduled substances and creating protections for banks and depository institutions who provide financial services to marijuana-related businesses[23].
2022 – Rep. Nancy Mace (R-SC) – H.R.9702 – “Amend IRC of 1986 to allow deductions and credits relating to expenditures in connection with marijuana sales conducted in compliance with State law” titled based on its intention[24], this bill would have appended the current 280E language to allow standard tax deductions for state licensed cannabis businesses.
2022 – Sen. Chuck Schumer (D-NY) – S.4591 – “Cannabis Administration and Opportunity Act (CAOA)” would have legalized cannabis at the federal level and provided a number of reforms for the cannabis industry, such as expungement of federal marijuana convictions and tax relief for state-legal cannabis businesses[25].
Despite significant lobbying efforts, these bills have failed to gain sufficient and timely bipartisan and bicameral support. In 2023, the relevant bills are once again “Small Business Tax Equity Act” (H.R.2643) filed by Oregon Representative Earl Blumenauer and the “Marijuana 1-to-3 Act” (H.R.610) from Florida Representative Greg Steube, with the same aims as previous filings. Cosponsors of the Small Business Tax Equity Act include Representatives Nancy Mace of South Carolina, Barbara Lee of California, Danny Davis of Illinois, and David Joyce of Ohio.
Reclassification of cannabis has been pursued by many industry advocates, which could mitigate the current tax burden. Controlled substances are defined in 280E as all schedule I and II substances of the Controlled Substances Act, from the five possible categories. Interestingly, the naturally occurring compound cannabidiol is classified as a Schedule V[26] drug, and the synthetic cannabinoid dronabinol is listed as a Schedule III[27] drug; both compounds have received approval from the FDA for safe and effective medical uses[28] – since 1985[29] in the case of dronabinol. Advocates at state and federal levels have argued for the reclassification of cannabis given its medical uses in many states. The DEA stands by the scheduling of cannabis[30], and as recently as 2016[31] said “Marijuana lacks accepted safety for use under medical supervision. At present, there are no marijuana products approved by the U.S. FDA” after a five-year evaluation process. Complete declassification is favored within the industry to eliminate the discrepancies between state and federal law related to cannabis. However, the DEA has issued a statement that “in view of United States obligations under international drug control treaties[32], marijuana cannot be placed in a schedule less restrictive than Schedule II.”
Reform efforts are ongoing. In October of 2022, President Biden requested that the Department of Justice and Department of Health and Human Services expeditiously review how marijuana is scheduled under federal law[33]. Both Departments committed to this[34], though a timeline for their discovery has not been provided. Congress and the Presidential Administration each have the ability to re- or de- schedule cannabis[35].
Current Impact
Today, the vast majority of states have legalized cannabis for medical use, along with 23 states and the District of Columbia allowing for recreational use[36]. Despite this public support, 280E is still being applied to licensed cannabis businesses, including those providing medical cannabis to patients with a prescription. The result is increased tax liability and reduced profitability for safe and regulated businesses. Given two companies – one a cannabis retailer and the other a retailer not impacted by IRC section 280E – with the exact same gross revenue, costs of goods sold, and gross income, the non-cannabis company will have a lower taxable income due to allowable standard business deductions, and therefore less federal tax due, than the cannabis retailer.
The primary mechanism through which cannabis businesses can reduce their gross receipts is costs of goods sold (“COGS”). COGS most often includes the cost of raw materials, active manufacturing, and packaging materials. Many cannabis businesses choose to stretch the idea of an inventory item to increase overall capitalization, though this significantly increases the risk of a tax audit. The IRS expects businesses to determine COGS consistently with IRC Section 471[37] and associated Treasury Regulations. Precise inventory records must be maintained to meet IRC 1.471 regulations[38], which specifically defines inventory capitalization rules with slight differences for cannabis processors[39] versus resellers[40]. Trades and businesses that are impacted by 280E cannot deduct charitable contributions or gifts as described in IRC Section 170[41], losses or depreciation as stated in Section 165 and 167 of the IRC, nor rentals or traveling expenses as defined in IRC 162(a)[42].
Comparatively, FDA regulated products such as alcohol, nicotine, sugar, and similar have excise fees that each business is responsible for, but none of these industries have restrictions on their gross or net income tax calculations. Most often, cannabis businesses are subject to 280E restrictions in addition to state and local excise or use fees. Generally, businesses can deduct certain taxes paid or otherwise accrued outlined in IRC Section 164(a)[43], but cannabis businesses cannot do so. Tax debt in the cannabis industry is a massive and pervasive problem. A 2022 Green Market Report analysis[44] showed that 10 multistate cannabis businesses owe over half a billion dollars in federal tax debt. In hopes of near-future tax code changes, forgoing tax payments is an intentional though unwise decision by cannabis operators.
It is critical to have compliant and reliable internal accounting systems in place to determine COGS, schedule all tax and fees due, and be prepared for an audit. Generally Accepted Accounting Principles[45] (“GAAP”) require accrual accounting, which recognizes costs and expenses as they occur as opposed to when they are paid. Cash or accrual methods may be used for cannabis business bookkeeping; income must be calculated for taxes via the same accounting methods as all other business records are kept. The IRS estimates that it audits 1.03% of business tax returns[46], and cannabis industry surveys[47],[48] have estimated that 6% of cannabis businesses have undergone tax audits, which indicates the IRS is especially interested in the tax compliance of cannabis operations.
State by State
Most states adopt federal tax policy directly to their own state level tax code as a matter of course; this includes section 280E. States and local municipalities may also apply an excise tax or use fees in addition to sales tax and income tax, which means that businesses should always check local ordinances for special taxes specific to the cannabis industry in addition to 280E. Fortunately, as states legalize cannabis use and encourage investments in local regulated cannabis operations, some officials have eliminated the unfair tax burdens for these new businesses.
Colorado was the first state to explicitly allow cannabis corporations[49] and individual[50] owners to take standard deductions on their income tax returns, with former Governor (now Senator) John Hickenlooper passing the legislation in 2014. Notably Washington state, where recreational cannabis was legalized the same year as Colorado, has no state income tax[51] and therefore cannabis operators in Washington have never been impacted by 280E at the state level.
Delaware is a standout state in regard to 280E. In their legislation initially legalizing recreational cannabis, provisions were preemptively made to allow for all ordinary and necessary expenses paid or incurred to be deducted from state taxes[52], including reasonable salaries, for all businesses operating in compliance with the state program.
Several states have adopted 280E exemptions exclusively for medical cannabis businesses. Arkansas does not generally conform to federal tax standards, and imposes tax on the net income of individuals and corporations with IRC 162 deductions allowed with no mention of restricted businesses.
If Arkansas moves forward with recreational cannabis in the future without specific related changes to their tax code, recreational operators in the state will not be impacted by 280E.
Effective for tax years beginning after December 31, 2015, Hawaii allows taxpayers engaged in medical marijuana businesses to deduct ordinary business expenses and claim tax credits on their income taxes.
In Maine, registered marijuana caregivers or dispensaries[53] can subtract from their state level gross income the amounts disallowed by 280E for tax years after 2017.
Montana also changed their tax policy in 2017 to allow licensed medical marijuana businesses to deduct ordinary and necessary business expenses.
Minnesota also allows subtractions on state income taxes[54] for federally disallowed IRC 280E expenses for medical cannabis operators.
Louisiana began to accept deductions on state level income returns in 2021 for expenses related to the production or dispensing of marijuana exclusively recommended for therapeutic use[55] by patients clinically diagnosed as suffering from a debilitating medical condition as defined in R.S. 40:1046(A).
For tax years 2022 and forward, licensed cannabis businesses in Missouri can subtract business expenses from their gross income on tax returns, provided by the state Marijuana Business Deduction.
In March of 2023, the District of Columbia passed into law several changes[56] for their medical marijuana program, including the allowance of typical business credits and deductions related to 280E on tax returns, and the unique adoption of a permanent sales tax holiday every year from April 15th until April 24th, in which no sales tax will be collected from medical cannabis sales in the District[57].
States that have created specific tax provisions for all cannabis businesses include New Jersey, where Governor Phil Murphy recently passed A-3946/S-340 into law, which allows cannabis businesses the option to deduct their expenses when filing state taxes.
Connecticut is the newest state to decouple from the federal tax code in regard to 280E, with Governor Ned Lamont signing H.B.6941 into law on June 12th of 2023. The law specifies[58] that deductions claimed under IRC 162(a) but forbidden under 280E are now permitted for any taxpayer licensed under the Connecticut state program.
Illinois will no longer copy 280E at the state level since Governor J.B. Pritzker passed HB 3817 into law[59] earlier this year. Cannabis operators licensed under the state Cannabis Regulations and Tax Act can now deduct necessary and regular business expenses from their state income, which will reduce their overall tax liability.
States that enacted similar legislation in previous years include Vermont, where normal deductions and exemptions are allowed for all cannabis businesses[60], and California[61], Massachusetts, Pennsylvania, Michigan, and New Mexico.
Oregon has allowed cannabis businesses to deduct expenses that would otherwise be permitted, if not for 280E, since 2016, and in 2023 enacted a rule[62] that directs companies to provide proof of tax compliance to the Commission to maintain or renew their license.
New York state passed budget provisions that allow licensed cannabis businesses to take ordinary tax deductions for tax years beginning in 2023, and New York City is set to copy this change later this year.
Other states have attempted to pass similar measures but have lacked the necessary support. Earlier this year in Virginia the state Senate unanimously passed a bill that would allow current licensed medical cannabis operators in Virginia to take standard tax deductions; the bill was subsequently voted on and opposed in the state House of Delegates. Rhode Island Senator Jonathon Acosta and Representative Scott Slater recently introduced R.I.S.B.968 and R.I.H.B.6209, respectively, which would allow licensed medical cannabis establishments to claim any deductions to income that would be allowable under the laws of the US but for 26 USC 280E; the House and Senate versions of these bills have both been recommended to be held for further study. Senator Young of Maryland introduced S.B.333 in 2018 that would create a subtraction modification for certain business expenses related to medical cannabis cultivation, processing, dispensing, and testing; the bill was cross-filed in the house, but stalled after referral to multiple committees. Maryland officials have reintroduced the bill in each legislative session since and it has faced an identical demise. Oklahoma currently has three bills, S.B.1117, S.B.389, and H.B.2101, introduced to the state legislature to remove the 280E burden from licensed cannabis operators in the state.
The Future of 280E
The future of IRC 280E is uncertain. President Biden has made promises about rescheduling cannabis as Schedule III-V, which would remove it from the 280E umbrella and would not impact current tax debts. There is a related joint scientific review from the US Department of Health and Human Services and the DEA in progress; the President expects the DEA will make the final scheduling determination based on this evaluation[63].
It may be found in court that 280E as applied to cannabis operators is unconstitutional in the context of federalism[64],[65] – as argued in the Supreme Court case[66] Alpenglow Botanicals v USA – since the public majority[67] have given their approval for cannabis and the majority of states[68] have a medical cannabis program, yet the government still influences the direction of the industry through taxation.
Individual states have made changes in favor of cannabis operators, and the rate of positive change thus far this year is exceptional and likely to continue. There are current bills in the House and Senate for 280E amendments and otherwise in support of fair taxation for cannabis businesses. Significant advocacy has happened for similar bills, but serious persistent efforts are still needed to move the industry forward.
Conclusion
To summarize, cannabis businesses maintain compliance with IRS tax code 280E by not taking the types of deductions detailed herein, even though the denial of these deductions for ordinary expenses results in an unfair business taxation on gross income. Additionally, state and local tax codes can change quickly, retroactively, and with little to no notice, and there are additional tax decisions for cannabis business owners including business structure, IRC compliance, and Financial Crimes Enforcement Network documentation. For deep industry insider guidance to ensure unwavering compliance with 280E and all other federal, state, and local tax codes and regulations, contact Cannabis Consultants Group for expert guidance. Stakeholders can also get updates from the IRS about 280E on the agency’s website specifically for cannabis business owners[69].
[62] Oregon Office of the Secretary of State. Temporary Administrative Order Including Statement Of Need & Justification for Department of Revenue Rev 12-2023, Chapter 150. Accessed at
This article exhaustively details all the information that you need to win a cannabis license in New York. Details of the history of cannabis legalization in the state are outlined, including draconian drug laws instituted in 1973, along with information about the previous and current political administrations views on cannabis, and how cannabis legalization came to be in New York. A summation of medical cannabis licenses include the technical details of that application round, general rules regarding medical cannabis and patients, legal battles related to medical licensees, and how medical operators will expand into the adult-use market.
Social Equity is a critical component of the cannabis legislation in New York; the equity requirements put forth by the original cannabis act, the Social Equity Cannabis Investment Fund, the 2023 Social and Economic Equity Plan, and the review process for social equity applicant consideration are all discussed in the Social Equity section. Finally, recreational cannabis licenses in New York are described in depth, including details on the brand new Cannabis Growers Showcase. Adult-use licenses are currently divided between conditional licenses and standard licenses; conditional licenses have already been awarded to social equity applicants, whereas applications for the standard license are set to be released this fall. Read on to learn how you can win.
History of Cannabis Legalization in New York
1973
New York State passed the Uniform Controlled Substances Act in 1973, following the federal lead to classify cannabis as a Schedule I substance[1], with no currently accepted medical use and a high potential for abuse.
1973
Governor Nelson Rockefeller, previously a proponent of drug rehabilitation through social programs, passed a set of drug laws that introduced the most severe criminal punishments nationwide for certain items, including a minimum of 15 years in prison for possession of four ounces of cannabis[2]. These laws are often collectively referred to as the “Rockefeller Drug Laws.”
1977
Governor Hugh Carey repealed sections of the Rockefeller Drug Laws that related to cannabis and passed the Marijuana Reform Act of 1977 with the intent in reducing the number of arrests and criminal prosecutions throughout the state related to cannabis use and possession[3].
2001
The New York Assembly proposed a bill that would legalize medical cannabis, which passed the Senate but was then vetoed by Governor Pataki.
2009
The New York Assembly proposed and passed a bill that would legalize recreational cannabis, but it did not pass the Senate.
2013
State Senator Liz Krueger introduced the Marijuana Regulation and Taxation Act (“MRTA”) in December[4]. The legislation would legalize, regulate, and tax marijuana under state law along lines similar to the state’s current system regulating alcohol. This Act would have allowed for home cultivation of up to six marijuana plants and empowered the State Liquor Authority to grant licenses for marijuana production, transport, and retail sale, among other measures to regulate marijuana within the state. The Act was referred to the Rules committee and the committee on Health before the session ended; no floor votes were held related to this bill.
2013
Senator Diane Savino introduced the Compassionate Care Act to the senate as S7923. Her co-sponsors included republican Senators William Larkin and George D Maziarz; an identical version of the Act was introduced by Assemblyman Richard N. Gottfried, which was referred to committees and advanced to third reading before the year ended[5].
2014
Governor Cuomo, a previous opponent of any cannabis legalization, signed the Compassionate Care Act into law, legalizing medical cannabis use in the state of New York. The medical cannabis program took an additional 18 months to launch, and offered non-smokable products to patients.
2014
Senator Tom O’Mara and Assemblywoman Donna Lupardo filed identical bills, S07047[6] and A09140[7] respectively, to authorize the growth of industrial hemp[8] as part of an agricultural pilot program. This filing came shortly after the related federal Agricultural Act of 2014[9] passed.
2015
The Industrial Hemp Agricultural Research Pilot Program launched[10], which permitted 10 approved educational institutions to grow and research industrial hemp and was overseen by the state Department of Agriculture. One goal of this program was to legitimize and encourage industrial hemp cultivationin the state.
2017
The Industrial Hemp Pilot Program expanded in 2017, allowing for an unlimited number of authorized sites to grow and research the plant. The expansion also allowed farmers and businesses to join the program. These farmers, unbeknownst to them at the time, have an advantage in recreational cannabis licensing.
2017
Governor Cuomo established industrial hemp as an agricultural commodity under the State’s Agricultural and Markets Law. The Governor concurrently announced[11] up to $10 million in grant funding to advance industrial hemp research and economic development opportunities for industrial hemp businesses; $5 million was designated for research, and the other $5 million was set aside for eligible businesses in need of capital for processing industrial hemp or for new construction.
2018
Governor Cuomo ordered the New York Department of Health to conduct a study on the possibility of safely legalizing recreational cannabis within the state; a particular impetus was legalization in the neighboring state of Massachusetts. By July of the same year, the study found that the benefits outweighed the potential negative impacts of legalizing marijuana for recreational use with a well-monitored and executed program[12].
2021
In January of 2021, Governor Cuomo attempted to legalize adult-use cannabis with the inclusion of the Cannabis Regulation and Tax Act (“CRTA”) in the state budget proposal. Instead, the New York State Assembly[13] and Senate passed their own bill, which Cuomo immediately signed into law on March 31, 2021. This resulted in previous marijuana-related criminal records in the state of New York being expunged, and created regulatory entities for the licensure of recreational cannabis businesses.
Political Environment for Cannabis Licensees
Previous Administration
Several consecutive Governors in the state of New York have been adamantly against cannabis legalization, which has created a slow start to the industry despite consistent support from the State Assembly. In 2002, the New York Assembly and Senate passed a bill that would have decriminalized marijuana possession and legalized medical use, which was then vetoed by Governor Pataki. He held the gubernatorial office until 2006 and vetoed all similar bills.
The directly subsequent Governors Eliot Spitzer (2007-2008) and David Paterson (2008-2010) both supported medical cannabis but not recreational use, but neither passed corresponding legislation. Governor Andrew Cuomo opposed marijuana legalization for medical or recreational use prior to his inauguration[14], and repeatedly drew the same conclusion that legalization of medical cannabis is not worth the risk; in an interview on April 23, 2013 Governor Cuomo said he does not support medical marijuana legalization[15]. In January of 2014 Governor Cuomo voiced his support for a state-led program that would allow medical marijuana access to 20 approved hospitals in the annual State of the State Address[16]; later that year he signed the Compassionate Care act into law. Seven years later, Governor Cuomo ratified the Senate and Assembly passed MRTA[17] into state law on March 31, 2021.
New York municipalities had the option to opt-out of allowing certain types of cannabis establishments. Local councils had to submit their opt-out request to the Office of Cannabis Management prior to December 31, 2021[18]. More than 50% of New York localities do not permit cannabis retailers or on-site consumption businesses. The official opt-out list is available for download from the OCM website[19]. On the upside, these localities are less populated and represent less than 25% of the state population[20]. No additional municipalities can opt-out, though any areas can choose to opt back in at any time.
Current Administration
Upon the appointment of Governor Hochul in August of 2021, there was not yet infrastructure in place to license recreational cannabis businesses, despite legalization; the Governor announced in March of 2022 the Seeding Opportunity Initiative[21], which allows individuals with prior cannabis-related criminal offenses to make the first adult-use cannabis sales with products grown by New York farmers.
In early 2022 Senator Michelle Hinchey introduced Senate Bill S8084A[22] and Assemblymember Crystal D Peoples-Stokes introduced corresponding Assembly Bill A9283[23]. These bills were passed into law in February of 2022 to create a conditional adult-use cultivator license, and a separate conditional adult-use processor license. The conditional cultivator license allows for the cultivation of adult-use cannabis, and until June of 2023 also permits cultivators to minimally process cannabis and distribute their cannabis products. The processor license allows businesses to process cannabis that has been purchased from licensed cultivators, and upon OCM approval may also distribute their own products. Senator Liz Krueger, Senate Majority Leader Andrea Stewart-Cousins, Assembly Majority Leader Crystal Peoples-Stokes, and Assembly Speaker Carl Heastie were all critical supporters in the passing of this cannabis legislation.
The 2023 New York legislature continues to support cannabis reform, and current Governor Kathy Hochul has developed positive working relationships with each of the entities regulating cannabis within the state. The Governor authorized the New York Social Equity Cannabis Investment Fund (“the Fund”) in the 2022-23 fiscal budget, which the legislature enacted in the same session. The Fund is a public-private limited partnership that will support social equity cannabis entrepreneurs in New York through the identification and leasing of suitable retail locations and the necessary design and construction to become operational. Licensees must pay an ongoing program fee to the OCM for rent and any loans, though licensees are not liable to repay loans issued from the Fund if they default[24]. The Fund is supported by up to $50 million in licensing fees and revenue from the adult-use cannabis industry and up to $150 million from the private sector that will be raised by the fund manager. In June of 2023, Governor Hochul announced that $150 million was contributed towards the fund from Chicago Atlantic[25].
The NY 2023 budget also included new 280e tax provisions for licensed cannabis businesses. New York Senate Bill S8009C[26] part PP was written to direct specific related changes to the tax code. Disallowed deductions under the federal tax code section 280e will now be permitted in calculating net income and adjusted gross income tax for New York state-licensed cannabis businesses.
The Governor launched an educational campaign this spring focused on safe, informed, and legal purchases of adult-use cannabis[27]. The campaign provides information on licensed dispensaries and explains safe cannabis consumption. Governor Hochul added to the 2024 NYS budget funds for increased inspections and penalties for unlicensed cannabis retailers throughout the state[28].
Cannabis Regulatory Bodies
The MRTA legislation[29] created a new Office of Cannabis Management (“OCM” or “the Office”) to comprehensively regulate adult-use, medical, and hemp cannabis. The Office includes five executive leadership members, a Chief Equity Officer, General Counsel, and three senior leadership members. The inaugural and current Executive Director of the OCM is Chris Alexander, appointed by Governor Kathy Hochul in September 2021; he has previously worked as the Government Relations and Policy Manager for a multi-state cannabis company, as an Associate Counsel for the New York State Senate, and Policy Coordinator for the Drug Policy Alliance, he also contributed writing and counsel on drafts of MRTA. Chief of Staff and Senior Policy Director for the OCM is Axel Bernabe; he previously spent six years as Chief Health Counsel to Governor Andrew M. Cuomo, during which he led the expansion of the medical cannabis program, directed the launch of the State’s cannabinoid hemp program, and drafted and negotiated MRTA. Additional members of the OCM executive leadership team include Patrick McKeage, Stanley De La Cruz, and Mary Adelaja. Damian Fagon was appointed as the Chief Equity Officer of the Office in June of 2022; he is a 3rd-generation farmer with a background in international development, agriculture and small business, has led development initiatives with castor farmers in Jamaica, rice growers in Sierra Leone, and coffee exporters in Guatemala, and he has launched and advised commercial cannabis operations in South Carolina, New York, and the Caribbean. The senior leadership team includes John Kagia as the Director of Policy for the Office of Cannabis Management, Nicole Quackenbush, Pharm.D. as the Director of Health and Safety, and Amanda Wilson as the Director of Administration.
The OCM is governed by a five-member Cannabis Control Board (“CCB”). The CCB is the approval and oversight body for the OCM. The CCB is responsible for approving the comprehensive regulatory framework for New York’s cannabis industry, including issuing applications and licenses to cannabis businesses and approving the rules and regulations which will govern the new industry. Meetings and documents from the CCB can be found on their website[30]. The CCB is chaired by Tremaine S. Wright, a former member of the NYS Assembly who thereafter served as the first Director of the DFS Statewide Office of Financial Inclusion and Empowerment. Additional CCB members include Adam W. Perry, Jessica Garcia, Dr. Jennifer Gilbert Jenkins, and Hope Knight. Hope Knight was nominated by Governor Hochul to the position of President, CEO, and Commissioner of Empire State Development, New York State’s economic development agency; she serves concurrently as Commissioner and to the CCB. Linda Baldwin serves as General Counsel to the CCB and to the OCM; she has previously served for over nine years as the General Counsel at the NYS Department of State and as the Director of the SMART Office at the U.S. Department of Justice. Adult-use cannabis business licenses are approved by the CCB and issued by the OCM.
A Cannabis Advisory Board (“CAB”) provides guidance and recommendations about cannabis and hemp use and regulation within New York to the OCM and the CCB. The CAB also administers the New York State Community Grants Reinvestment Fund in accordance with Section 99-kk of the State Finance Law. The CAB has 13 voting members including cannabis farmers and medical doctors, each appointed by the Governor and approved by the NYS Senate and Assembly. Professional subject matter experts from various state agencies regularly provide opinions or reports to the CAB. The board is chaired by Joe Belluck, and vice-chaired by Dr. Junella Chin, M.D.; other voting members of the board include Alejandro Alvarez, Ebro Darden, TheArthur A. Duncan, Allan Gandelman, Garry Johnson, Nikki Kateman, Marc Ramirez, Sarah Ravenhall, Chandra Redfern, Armando Rosado, and Peter Shafer. Meetings and documents from the CAB can be found on their website[31].
New York Medical Cannabis Licenses
Technical Details
The New York Department of Health initially oversaw the New York medical cannabis program. Oversight changed to the OCM upon its creation. The Department began accepting applications for registration as a Registered Organization (“RO”) on April 27, 2015 and the window closed on May 29, 2015[32]. All application materials were due by mail to the Department of Health. Each applicant was required to submit two fees with its application: a non-refundable application fee in the amount of $10,000, and a registration fee in the amount of $200,000. The $200,000 registration fee is to be refunded to the applicant only if the applicant is not issued a registration. The Department received 43 applications from businesses interested in becoming ROs to manufacture and dispense medical marijuana under the Compassionate Care Act[33]. The law provides for the initial registration of up to five organizations in New York State and allows the Commissioner to register additional organizations in the future. Each RO may operate up to four dispensing facilities statewide, for an initial total of up to 20 geographically-dispersed dispensing facilities. Within a year, the Department awarded licenses to an additional five businesses from the original group of applicants, bringing the total number of medical dispensaries up to 40. A list of current medical cannabis dispensaries is available on the OCM website[34]
General Rules
Medical cannabis is available for many diagnoses in New York state, including cancer, HIV/AIDS, amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis, damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity, epilepsy, inflammatory bowel disease, neuropathies, Huntington’s disease, post-traumatic stress disorder, pain that degrades health and functional capability where the use of medical cannabis is an alternative to opioid use, substance use disorder, Alzheimer’s, muscular dystrophy, dystonia, rheumatoid arthritis, autism, or any other condition certified by the practitioner. A public list of health practitioners certified in medical cannabis is available from the NY Department of Health[35]. Once a medical practitioner has certified a patient, they can visit a medical dispensary and purchase up to a 60 day supply. No medical card is required for patients in New York. Each certified patient can designate up to five caregivers.
Available medical cannabis products include vaporization pens, capsules, tinctures, oral spray, oral powder, lozenges, pre-measured and pre-ground cannabis flower for vaporization, whole flower cannabis for vaporization, and transdermal patches. Seeds and immature plants for home cultivation are also available for sale to certified patients.
Medical cannabis dispensaries in New York State have pharmacists on-site to help patients find the right product for their conditions, check for interactions with other medications, and show patients how to use each form of cannabis. There are education and training requirements specific to cannabis, created by the Department, for each registered physician. The Compassionate Care Act, which originally legalized medical cannabis in New York, prohibited smoking for medicinal purposes; this restriction has since been removed.
Patients can cultivate cannabis at home for their own medicinal use; one certified caregiver can support this task. All cannabis plants must be secured[36]. One patient can have three mature and three immature plants in their private residence at one time. Restrictions on home cultivation likely apply to individuals in rented or public housing, despite certification as a medical cannabis patient. The OCM has created a medical home cultivation guide for patients[37].
Regulations
All ROs must implement a security system to protect their products, which must include alarm and video surveillance systems that are digitally accessible to the OCM. ROs may only manufacture medical cannabis products in forms approved by the OCM[38]. Any extraction performed must be done by trained personnel in a safe area with proper ventilation. Allowable methods of extraction include mechanical, steam distillation, closed loop CO2 gas extraction, ethanol, or hydrocarbon. Final products must be tested for their cannabinoid profile, as well as for various contaminants and pesticides. The testing of each lot of final medical cannabis product must be conducted with a statistically significant number of samples using acceptable methodologies. ROs are also required to provide a package safety insert to patients. Information in the insert must include any excipients used, an allergen warning, medical contraindications, adverse effect warning, and details of substance abuse. All sales conducted at ROs must be tracked, and can only be made to certified patients or their designated caregiver.
Application Requirements
The application for a RO requires information about the business name, structure, and primary business contact, location of manufacturing, location of cultivation, and each dispensary location, with proposed hours of operation for all of the above[39]. Legal disclosures, financial statements, property blueprints, architectural program[40], a business plan, equipment descriptions, affidavits from each stakeholder[41], organizational charts, a labor peace agreement, proof of internet accessibility, and a timeline to start operations are all necessary. A ten part operating plan is also required with this application; required subsections include manufacturing; transport and distribution; dispensing and sale; devices; security and control; standard operating procedure; quality assurance plans; returns, complaints, adverse events, and recalls; product quality assurance; and, recordkeeping. Each applicant must further define how they will produce sufficient amounts of cannabis for the medical market, create consistent products, and prevent diversion.
Legal Issues
The Department of Health was the original governing body for medical cannabis, and oversaw the program launch in January of 2016. Upon their attempt to expand the amount of medical cannabis operators in the summer of 2016, the five current ROs filed a collective lawsuit against the Department. Their suit argued that the market was too small for additional licensees, that their own operations needed more time to flourish, and that competition so early on would lead to an industry collapse. Three of the five operators, Etain Health, PharmaCann, and Vireo Health, had owners openly state in summer 2016 interviews that their businesses were not yet profitable[42]. Despite these concerns, the Department did move forward with the medical cannabis program expansion, allowing ten medical cannabis businesses in the state.
Later in 2016, two Vireo Health officers[43] were accused[44] of smuggling $500,000 worth[45] of medical cannabis products from their Minnesota based medical cannabis business into New York[46]. Those products were then supposedly sold to medical cannabis patients of New York. After a lengthy legal process[47], the individuals had criminal charges dismissed after completing 80 hours of community service.
The sixth medical cannabis business license was awarded to New York Canna, Inc. However, this license was transferred to a Delaware company, doing business as “NYCANNA, LLC” in 2017 without approval from regulators. This business is now under ownership by Acreage Holdings, a public company in Canada with cannabis operations in multiple US states[48]. A complaint filed in January of 2019 argues that the current ownership structure is illegal, and forced out New York based owners who were actually granted the license[49]. The case is ongoing.
In 2019, multiple allegations of professional misconduct were raised against the CEO of MedMen[50]. The company was asked by the New York Medical Cannabis Industry Association to resign from the organization as a result of the lawsuits, but it still operates multiple medical dispensaries in the state.
A 2023 lawsuit from the recently formed Coalition for Regulated & Safe Access to Cannabis was filed against the OCM[51]. It alleges that the social equity program has now created excessive barriers for a successful adult-use market[52]. The main goal of the lawsuit is to expedite the standard adult-use cannabis licensing process. The Coalition includes several current medical cannabis operators, including Acreage Holdings, Curaleaf, Green Thumb Industries, and PharmaCann, who will all likely apply for standard adult-use licenses as soon as possible[53].
Recreational Expansion
The 10 currently licensed ROs have two options if they choose to enter the adult-use market: a Registered Organization Non-Dispensing (“ROND”) license or a Registered Organization with Dispensing (“ROD”) license. The ROND license allows current medical licensees to distribute their cultivated and processed products to adult use retailers, and the ROD license allows current medical operators to sell products directly to adult consumers. Any RO that chooses to participate in the adult-use market must provide a plan to prioritize medical cannabis patients as part of their application. ROND and ROD licensees are required to comply with all regulations for adult-use businesses of the same license type. All ROD adult-use dispensaries must be co-located with one of the RO medical dispensaries.
These operators will be the only vertically integrated cannabis businesses in New York, and they may also apply for nursery licenses. Owners and stakeholders of a ROD cannot hold a direct or indirect interest in any other retail dispensary license and cannot operate an on-site consumption facility[54]. Until January 1, 2025, all RODs must dedicate at least 50% of their shelf space to products cultivated and processed by other licensees. This provision will support current conditional cultivator and processor licensees with excess product. After January 2025, this restriction shifts to a minimum of 40% shelf space. Recreational cannabis sales from RODs can begin as early as December 29th, 2023 from their current location, and can add another operational adult-use location after June 29th, 2024[55].
Special licensing fees apply to ROND and ROD licenses; both have a $10,000 application fee[56]. The ROND annual licensing fees are determined based on the scale of activities taking place, and are the same as standard adult-use licensees of the same type and size. ROD licensees will pay not only the standard licensing fees for each type of activity pursued, but an additional $175,000 for cultivation activities, and a one-time fee of $20 million dollars. The first installment of $5 million is due at the time of licensure, with additional installments due either within 180 days of opening a second adult-use dispensary location, or within 30 days of surpassing $100 million in business revenue. The fees are meant to fund the Social and Economic Equity Plan.
New York Cannabis Social Equity
The MRTA[57], which legalized recreational cannabis in New York, has several required provisions designed to promote social equity in the regulated cannabis industry. Specifically, the act automatically expunges past cannabis convictions provided the individual meets certain criteria; and, invests 40% of the adult-use cannabis tax revenue toward rebuilding communities that were disproportionately impacted by previous drug laws. Priority status is given to individuals from Communities Disproportionately Impacted (“CDI”) by the enforcement of cannabis prohibition; to provably distressed small farm operators; and, to businesses owned by a minority individual, woman, or service disabled veteran who provides at least 51% of the ongoing contributions and guidance to their business. Extra priority is given to individuals who were convicted of a cannabis-related offense, or had a parent, guardian, child, spouse, or dependent, or was a dependent of an individual who was convicted of a cannabis-related offense in the state of New York prior to March 31, 2021. Extra priority is also given to individuals with an income lower than 80% of the median income of the county in which they reside[58]. An additional mandate of MRTA is that 50% of all adult-use licenses must be awarded to social and economic equity applicants. The Chief Equity Office specifically oversees the social and economic equity initiatives laid out in the law; Damian Fagan was appointed to this role in June of 2022.
Governor Kathy Hochul introduced the Social Equity Cannabis Investment Fund (“the Fund”) in January of 2022, which provides qualified individuals with a turn-key retail dispensary in an ideal location. The Fund is a joint private and public venture, and cannabis sales tax revenue will be reinvested for Fund sustainability. In February of 2022, a Conditional Adult-Use Cannabis Cultivation license was announced by the Governor’s office[59], which would allow farmers already operating within the New York hemp program to expand their cultivation to include cannabis for the adult-use market while meeting sustainability requirements. All Conditional Adult-Use Cannabis Cultivators must participate in a social equity mentorship program where they provide training in cannabis operations for social and economic equity partners, preparing them for potential roles in the industry; the exact design of this program was decided at a later date, with more detail below.
In March of 2022, the Governor and the OCM announced the initial Seeding Opportunity Initiative[60]. Primary goals of this initiative included the prioritization of local farmers and individuals with prior cannabis-related criminal offenses, job creation, and giving the opportunity for the first licensed cannabis retail sales to communities that were disproportionately impacted by cannabis prohibition. Applications for conditional licenses began in mid-March for cultivators, late June for processors, and in late August for dispensaries; each application window was at least one month long.
With a plethora of positive press[61],[62],[63],[64] about how well the social equity initiatives would be implemented, the results have been lackluster – largely stymied by lawsuits regarding the licensing process, including from Michigan-based company Variscite. Variscite argued via a lawsuit filed in September of 2022 that they should have been selected among the first 150 equity dispensary operators in the Finger Lakes region, and declared the Conditional Adult-Use Retail Dispensary program unconstitutional. The social equity law of New York requires applicants to have a significant presence in New York, of which Variscite has none. A judge limited the number of dispensary licenses that could be issued in certain regions while this particular lawsuit was resolved. In late May of 2023, the CCB voted[65] for the OCM to settle the suit and allow forward movement in the industry; the settlement states that Variscite will automatically receive one of the first non-equity retail licenses issued in their selected jurisdiction and that all related lawsuits will be dismissed. There are additional lawsuits still in play regarding the OCM, but none are likely to have such a significant impact.
The 2023 Social and Economic Equity (“SEE”) Plan[66] was created with input from the community and includes several components to support equity applicants. The Office and the CCB identified five pillars of equity[67]: bringing to life an industry that gives small, independent businesses an opportunity to compete; building relationships and trust within the communities most impacted through educational and social programming; investing resources including grants, loans, and technical assistance to equip SEE groups with the support needed to thrive in the New York State cannabis market; educating communities on their rights in accordance with the Cannabis Law and regulations; and collecting data and evolving programming to adapt to the equity needs of the industry. Licenses issued as part of the SEE Plan cannot be sold or transferred within the first three years, except to a similarly qualified equity individual with Board approval.
One aspect of the NY SEE Plan is the creation of a formal incubator program, which will include physical locations for education. Existing incubators[68] are provided by Empire State Development in each of the ten economic development regions of New York[69]. The Office has created methods for social and economic equity individuals to reapply for licensure if they are rejected, after they complete an incubator program.
For cannabis-specific education and training for job seekers, Cornell University and the Workforce Development Institute have developed a partnership, partially funded by the state, that provides cannabis-specific education and training to job seekers titled the New York State Cannabis Workforce Initiative. Furthermore, the New York State Department of Labor Cannabis Employment and Education Development (“CEED”) Unit connects people with cannabis industry jobs.
Within the SEE Plan, the Office has developed a Cannabis Compliance Training and Mentorship Program, a 10-week virtual training program available to legacy cultivators, traditional farmers, and a combined cohort of legacy processors and traditional food and beverage processors, with direct support from currently licensed conditional adult-use cultivators and processors. The goal of the program is to expand and diversify the pipeline of cultivators and processors preparing to participate in the New York cannabis market[70].
Direct loan programs from the SEE Plan should be available in 2024, though specific requirements and timeline have yet to be released. An additional opportunity being explored is communal kitchens: authorized spaces where multiple licensed small-batch processors can utilize shared equipment.
The OCM has elaborated that the review process will actively try to identify individuals and businesses who deserve social equity consideration, even if they do not explicitly request for or apply under that term. All non-equity applicants must develop and implement a social responsibility framework designed to contribute to communities disproportionately harmed by cannabis prohibition[71].
New York Recreational Cannabis Licenses
New York has created several methods to obtain a recreational cannabis business license, whether the operator is a cultivator, processor, retailer, or other licensee. These methods include a conditional license, a provisional license, and a traditional recreational business license. The law creates a two-tier marketplace, in which the supply tier includes cultivators, processors, and distributors, and the retail tier includes dispensaries, deliveries, and on-site consumption lounges. Owners from the supply tier, which includes cultivation, processing, and distribution, cannot have an interest in a retail tier license. The tiered system purposefully prohibits vertically integrated operators.
All licensees must use the designated transportation manifest, developed and provided by the OCM, when moving any cannabis or related products between facilities. The manifest requires information about the originating facility, the responsible transporter, destination(s), all products by name, lot number, and weight, and a signature from the receiving party to complete the chain of custody. A downloadable version of the manifest can be found on the OCM website[72]. BioTrack has been selected as the New York seed-to-sale tracking system[73]. All licensees will be required to use BioTrack software for their cannabis inventory and allow the OCM access to their data upon request[74].
*CONDITIONAL
The conditional cannabis license process began with cultivator licensees, then processors, followed by retail dispensaries. Conditional licenses are only available to individuals who meet specific criteria, based on the license type pursued.
Technical Details
Cultivator
Applications for the Adult-Use Conditional Cultivator (“AUCC”) were submitted digitally to the CCB between March 15, 2022 and June 30, 2022. The only individuals allowed to apply for the AUCC license were those already authorized by the Department of Agriculture to grow cannabinoid hemp under the Markets Industrial Hemp Research Pilot Program. They must also have at least two years of successful cannabinoid hemp harvests within the last four years, maintain good standing with the Department of Agriculture, and only individuals with more than 51% ownership of the authorized farm can pursue an AUCC license. Each license was issued for two years, expiring in June of 2024, with additional documentation requirements from each operator at six months and one year post licensure. There have been more than 270 AUCC licenses approved by the regulatory bodies to date[75]. All AUCC operators that are in good standing with the OCM may apply and receive a standard Adult-Use Cultivator License, when available.
Processor
Adult-Use Conditional Processors (“AUCP”) had an application window of June 28, 2022 – August 31, 2022. Licenses were only available to businesses that were previously authorized to process cannabinoid hemp, and only individuals already authorized and practiced in extraction through the hemp program will be licensed to do so in the adult-use market. AUCP locations must be already approved cannabinoid hemp processing locations. AUCP licensees may request additional locations[76] to designate as distribution locations, intended for storage of cannabis products that are complete, tested, and packaged for distribution. 40 licenses were awarded[77] with a two year validity period[78] or until June 30, 2024, after which point businesses are meant to undergo the traditional processor license application. AUCP licensees who package cannabis products for retail sale must submit an annual sales report, which specifies the total amount of packaging material, by weight, sold, offered for sale, or distributed into the state by the licensee in the prior calendar year; the percentage of all packaging material sold, offered for sale, or distributed for sale in the state; and the total costs of packaging material.
Dispensary
The Office began accepting conditional adult-use retail dispensary (“CAURD”) applications in August 2022. These licenses prioritize businesses owned by “justice involved” individuals and up to 25 specific non-profit organizations[79] as “social enterprises.” Justice involved people include those who were convicted of a cannabis-related offense[80]; whose parent, spouse, registered domestic partner, child, legal guardian, or dependent was convicted of a cannabis-related offense; or who is the dependent of someone who has been convicted of a cannabis-related offense; if the arrest ultimately led to a conviction for another offense, such as non-drug offense, or lesser offense by means of a plea deal or other mechanism, it is still a qualifying justice involved situation; certain felony convictions within the last 3 years will require specific CCB approval and may result in disqualification; all related offenses must have taken place in the state of New York and prior to March 31, 2021[81]. CAURD applicants must be owned by a justice involved individual who controlled and owned at least 10% of a “qualifying business” for 2 years. Qualified businesses must have been owned by a justice involved individual for at least 2 profitable years, with that same individual holding at least 30% ownership in the proposed dispensary. The dispensary must be majority owned (51%) by justice involved individuals; multiple people can be combined to reach this percentage, though each person must provide documentation related to their equity status. CAURD applicants can have an ownership or significant interest in up to three other CAURD businesses.
Whether applying as a qualified business or as a non-profit, CAURD applicants must have a proven significant presence in the state of New York. Justice involved individuals must prove their place of residency[82] at the time of the related arrest or conviction, and provide proof of the event. Interested social enterprises must have a verifiable history of serving communities disproportionately impacted by cannabis prohibition, have at least one active board member or similar who meets the justice involved criteria, and have proven profits for at least two years of business.
Conditional dispensary applicants will select up to 5 regions in order of preference within New York for their retail location. The regions of New York State include: Brooklyn, Capital Region, Central New York, Finger Lakes, Long Island, Manhattan, Mid-Hudson, Mohawk Valley, North Country, Queens, Southern Tier, Staten Island, The Bronx, and Western New York. Licenses will be allocated among the 14 regions based on commuter-adjusted population[83]; applications will be scored and ranked based on their preferred location[84] and the top scoring applicants will be awarded a provisional license. CAURD businesses may also provide their own location for the retail dispensary, pending CCB approval. Social enterprise applicants have 6 months after their provisional licensure to secure a location. All CAURD applicants have 60 days after their location is finalized to complete all other necessary business arrangements.
There are multiple stages to the CAURD licensure process, including a provisional license award prior to location finalization. Many qualified business applicants are reliant on the OCM to receive a location and a loan for capital expenses through the Fund, since these are premium retail locations that are ready-to-operate, with banking and point of sale services[85] in operation and capital available for any necessary redesign or construction. Businesses that are provided a location for their dispensary from the OCM are not permitted to change the retail location while they have a conditional license.
Over 900 applications for a CAURD license were received within the application window, and 463 qualified businesses have been provisionally approved. Licenses are valid for two years from the date of issuance, at which point there will be a renewal process. The conditional period of the CAURD license ends four years after it was originally issued, and businesses that are in good standing with the OCM will have the opportunity to transition to a standard adult-use retail license prior to license expiry. On December 29th, 2022, the first CAURD location began public operation. A list of currently licensed adult-use dispensary operators is provided by the OCM[86] and all licensed dispensaries must display a verification QR code to curtail illegal sales.
General Rules
Conditional cultivators and processors agree to support the growth of the cannabis industry within NY state, particularly through social equity mentorship and environmental sustainability; this has come to fruition with the Cannabis Compliance Training and Mentorship Program, which launched in January 2023. Within six months of licensure, all conditional cultivators and processors must enter into a Labor Peace Agreement with a valid labor organization, to protect worker rights and avoid a spontaneous cessation of work through a strike or similar; conditional dispensary applicants must have an executed Labor Peace Agreement prior to final licensure. Conditional cultivators and processors are permitted to sell and otherwise distribute their own products until June 1, 2023, by which point they must acquire an additional distributor license.
AUCP licensees can produce topicals, edibles, single-serve beverages, vaporization cartridges, single-use vaporization pens, concentrates, tinctures, capsules, tablets, or any other product type or form with prior written approval of the Office. In determining whether or not to approve a new cannabis product type, the Office may request written submission by the processor of the proposal, including but not limited to the proposed manufacturing process, methods of administration and other factors to assess risk to public health and safety. No products can ever contain alcohol, tobacco, or nicotine.
Once CAURD licensees are granted a provisional license, they may apply for a temporary delivery only location. These locations are valid for up to one year, and authorized operations can continue from the designated temporary delivery location even after the permanent retail location is approved[87]. Licensees are permitted to receive licensed products from a cannabis distributor, take customer orders online or by phone, and deliver products to customer residences between 8 am and midnight.
Regulations
MRTA[88] was signed into law on March 31, 2021 and legalized adult-use cannabis in New York State. The OCM has developed additional regulations outlining how businesses can participate in the cannabis industry. While regulations are pending formal adoption, the Office has issued guidance documentation for current businesses to comply with.
The guidance for conditional cultivators was originally published in March of 2022, and most recently updated in January of 2023[89]. All AUCC licensees are limited to 1 acre of outdoor cultivation, or 25,000 square feet of indoor greenhouse cultivation, or a mix given that the greenhouse canopy is less than 20,000 square feet and the total flowering canopy is equal to or less than 30,000 square feet. No more than 20 artificial lights are permitted, and the entire premises must be secured. Cultivation can but is not required to take place at the location already licensed for cannabinoid hemp cultivation, and all hemp cultivation materials and operations must be kept distinct from adult-use cannabis. If AUCC owners choose to transition to the standard cultivation program in 2024, they will be granted a cultivation tier that allows for at least the same amount[90] of space as their current operations. Up to four AUCC licensees can share one facility[91], though all products and operations must be clearly distinguishable.
AUCC businesses are allowed to cultivate cannabis and to sell wet or dried cannabis, seeds, clones, and seedlings to other licensed operators[92] after it has passed relevant tests. Each facility must be maintained in a sanitary condition, including all equipment, processing areas, and storage spaces. Minimal processing of cannabis flowers to create pre-rolls was permitted for AUCC operators until June 1, 2023, after which only licensed processors can perform this function.
Within 30 days of licensure each AUCC is required to submit key parts of an Operating Plan for their business, with the full Operating Plan due to the OCM by six months post licensure, and at the end of the first year of licensure they must submit an Annual Cultivation Report to the Office. The Operating Plan at 30 days requires a site plan indicating the activities performed in each area, detailing all physical boundaries, roads, and water crossings of the property, a security and staff safety plan with risk mitigation and accident prevention plans based on a detailed risk assessment of all stages of cannabis production; parts of the plan to be submitted at six months are a cultivation plan with details of all cultivation, processing, storage, and record keeping policies and procedures; a soil preparation plan document with records of analysis, descriptions of soil quality, and a plan to promote healthy soil; an environmental impact plan that details the actions taken to maintain and improve ecosystem health and services with neutral or positive impact on biodiversity; a pest management and control plan document based on Integrated Pest Management (“IPM”) principles with details on prevention, observation, and interventional steps, and which consistent physical, mechanical, biological, and chemical methods were utilized; a cannabis sampling, analysis, and testing plan; a quality assurance plan that establishes criteria to detect, identity, prevent, and track harvested cannabis contamination incidents; a cannabis recall plan document that includes an annual mock recall test; a sustainable water-use and conservation document that addresses water sources, quality, and use; and a sustainable energy use and conservation document that addresses the sourcing and use of energy and sets energy efficiency goals including timelines and benchmarks.
The Annual Cultivation Report requires 29 significant sections, including an up-to-date site plan; physical inventory of cannabis, at any stage, and all associated labels, reflected accurately in an electronic inventory management system; detailed plant protection application records for any propagation treatments; documentation of a soil, soil mixture or substrate material assessment; an agricultural input list with product name, active ingredient, purpose, application rate, timing within life cycle of plant and method, Material Safety Data Sheet, Certificate of Analysis, product labels, and history of application; water usage per cultivation cycle; energy audit records; pest and disease monitoring and scouting records; lab results from an approved NY State cannabis testing laboratory for all required testing for cannabis from each production cycle; records of plant removal and destruction of all cannabis not meeting minimum quality, strain, and safety standards; equipment maintenance and upkeep records; records of all employees and independent contractors; staff health and safety procedures; signed consent forms from all employees and independent contractors that apply chemicals as part of their work activities; records of routine cleaning of all containers, tools, and equipment; records of routine cleaning and sanitizing of all areas of the facility where cannabis is produced, handled, or stored; pest management records that include a map of all traps, records of routine trap maintenance, and record of any evidence of animal or insect presence including body parts, hair, or feces in cannabis handling areas; records of an annual mock recall; records of all complaints received along with the defined timeline for each response and name of persons responsible for complaint procedures and actions taken; production water analysis results; post-production water analysis results if there is any water runoff or discharge; waste disposal records including material resulting from the trimming process, as well as composting or other disposal or remediation methods; a visitor log; a signed copy of the labor peace agreement; and an overall indication of compliance with guidance and regulations, and is subject to comment and feedback from the Office. Failure to promptly submit all required documents may result in a revocation of the conditional license.
AUCC licensees must continuously abide by all regular rules promulgated for adult use cultivators in section 68 of the Cannabis Law[93].
Transitions from the conditional cultivation license to a standard adult-use cultivation license, once available, will be determined by a number of factors, including environmental impact. Specifically, the OCM and CCB will evaluate green-house gas emissions reduction, waste reduction efforts, efficient irrigation systems, and renewable power generation. During the standard adult-use licensing period, AUCCs can transition to a tier 1 – tier 4 outdoor cultivation license, tier 1 or 2 of mixed-light or combination cultivations, a cooperative, or a microbusiness[94].
In addition to the labor peace agreement and mentorship program previously mentioned, the guidance for AUCP licensees requires extensive recordkeeping, that each facility be maintained in a sanitary state, and that Good Manufacturing Practices (“GMP”) are followed. GMP refers to a quality control system for ensuring that products are consistently produced and controlled in accordance with 21 CFR Parts 111 and 117 by the FDA. For businesses performing extraction, generally only extraction techniques and activities that have been previously approved within the cannabinoid hemp program will be allowed for a given business. Extraction based businesses must maintain proper ventilation, demonstrate control over all ignition sources, record all solvents used with proof of their purity, and only allow trained employees to perform extraction activities. Products that can be produced by an AUCP include topicals, edibles, single serving beverages, vaporization cartridges, vaporization single-use pens, concentrates, tinctures, capsules, tablets, and cannabis flower products such as pre-rolls. No products can exceed more than 10% total terpenes, and detailed records must be maintained of all cannabis or botanically derived terpenes used in products.
All products sold at retail must have warnings on the label, and can never intentionally appeal to kids or anyone under 21. Youthful marketing to avoid includes cartoons, neon colors, silly spellings of words such as “wordzz” or “kandy” for candy, or the inclusion of any characters, games, or toys that commonly appeal to this demographic. A universal cannabis symbol is required on all products; the symbol is pictured here and is available for download on the OCM website.
In March 2022, the CCB issued proposed regulations for the CAURD licensees for public comment. The public comment period closed on May 31, 2022. On July 14, 2022, the Cannabis Control Board approved the final rules and regulations for the CAURD licensing program. These were added to the Official Compilation of Codes, Rules and Regulations of the State of New York as Part 116 under Chapter II of Subtitle B of Title 9[95]. The regulations provide definitions related to the CAURD program; details on the application requirements; details on license eligibility, evaluations, and denials; license renewal and transition information; and information on ownership rules and restrictions. Once a CAURD applicant has an approved location, they must provide notification[96] of their intent to the local council where they plan to operate; this notification has to be made by certified mail, return receipt requested; overnight delivery service with proof of mailing; or through personal presentation of the notice.
CAURD licensees are permitted to purchase tested cannabis products from a licensed distributor for resale into the adult use market. The entire retail facility must be secured, and cannabis may not be accessible to any unauthorized staff or visitors. A complete inventory must be available at all times, and each sale must be tracked in a manner that integrates with the OCM seed-to-sale tracking system. Sales of cannabis can only be made to people over the age of 21, and their identity must be verified. Deliveries of cannabis products are permitted by car, van, bike, scooter[97], or foot, so long as the delivery employee is properly trained and the products are secured for the duration of the trip.
Application Requirements
AUCC
Each conditional cultivation applicant was required to provide a business plan, cultivation plan, and floor plans in addition to ownership information, an organizational chart, financial details, and proof of valid participation in the cannabinoid hemp pilot program. Each submission also required a $2,000 non-refundable fee.
AUCP
Each conditional processor applicant was required to provide[98] proof of licensure to process cannabinoid hemp prior to January 1, 2022, proof of passing a Good Manufacturing Practices audit, basic information about the applicant and the proposed location, a list of which products will be processed, and detail any extraction methods to be undertaken, along with a $2,000 non-refundable submission fee. Additional business documentation including a capitalization table, an organizational chart, details of funding sources, and a description of the proposed business model were also required. For licensees interested in hydrocarbon extraction activities, a document of approval from the local fire marshal or similar authority and proof that the proposed location complies with all applicable building and fire codes was also required. This process was completed primarily in the OCM application portal, with payment due by mail.
CAURD
There are multiple steps to the CAURD application, including the initial application, provisional license award, dispensary location approval, and post-selection application, before the final license is granted.
For the initial application, each business needed to submit proof of their social equity status, with available methods including a certificate of disposition, a record of judgment, a record of plea, verdict, and sentence, a court docket entry that indicate the conviction, an arrest record, a police file, notarized attorney letters, acknowledgement of application to destroy expunged cannabis conviction record, a Governor’s commutation letter, results from a criminal history background check, or any other information that can be used by the OCM to verify the related offense. Details about all true parties of interest, individual and business tax documentation, ownership structure, and financial disclosures are also required for the initial application.
The post-selection application requires all of the previous information to be confirmed, and asks for a dispensary site plan; a Department of Tax and Finance Certificate of Authority and Tax clearance forms[99]; documentation for worker’s compensation insurance, and disability and paid family leave benefits insurance; a management staff roster and organizational chart for the dispensary; a delivery plan when relevant; a labor peace agreement; ownership deed or signed lease agreement for the approved location; proof of notification to your municipality; a valid certificate of occupancy; vendor contracts for inventory tracking; and a copy of any other pertinent licenses or permits. Applicants must designate an Employee in Charge[100] who is 21 or older; they will be responsible for managing the core day-to-day functions of the dispensary, maintaining an adequate staffing plan, and submitting required reports and notifications to the OCM. Each licensee must maintain a written training manual[101], available to all employees. The training manual must include worker guidelines, specifically security, operating, and safety procedures, regarding daily opening and closing procedures; security, customer admittance, and customer traffic-control procedures; ordering and point of sale procedures; delivery service procedures; product inventory intake procedures; product return and disposal procedures; emergency procedures; an explanation of how workers will monitor for and prevent underage sales; information about all types of cannabis products the dispensary sells including product types, serving sizes, duration of effects, methods of administration, usage warnings, secure storage instructions, proper disposal instructions, customer confidentiality requirements, and alcohol-free, drug-free, and smoke-free workplace policies.
Cannabis Growers Showcase
With legal issues hindering the approval of dispensary licenses, a significant number of licensed AUCCs have excess cannabis products that are set to expire soon. The AUCC business models and cultivation plans were based on projected retail numbers from the OCM, which have not yet been realized. As a momentary solution, the OCM has created a Cannabis Growers Showcase (“CGS”) to allow consumers to see and purchase AUCC and AUCP products without a traditional dispensary storefront. CGS is a temporary program set to expire on January 1, 2024 and the last applications will be accepted on December 1, 2023. Applications require information about each participating business, proposed products for sale, a basic site plan, inventory data templates, municipal approval, and contact information for an Employee in Charge, and must be submitted at least 10 days before the planned event (or at least 20 days before the planned event, after September 5th).
The OCM presented the CGS concept at their July 19th meeting, and opened applications the same day. A CGS requires at least one CAURD licensee to host an event for up to 3 AUCCs. At least 1 of the AUCCs must be a new partnership for the CAURD. For every 3 AUCCs, 1 AUCP may also participate, and up to 35% of total CGS sales can be from processed products. CGS events can take place at a variety of locations, although temporary delivery only locations are specifically excluded. A supply tier licensee may not pay for, sponsor, or provide entertainment for the event. CAURD licensees must have final retail authorizations to participate in a CGS, which may include licensees with only temporary delivery operator authorization in certain situations. Events can be recurring, one time, or an event on consecutive days lasting less than two weeks. A public or private event with adult attendees can allow a CGS concurrently in their space. A CGS does not permit any one other than a trained employee of a CAURD business to complete a cannabis sale with a consumer. Sales of food, beverages other than water, tobacco, nicotine, or games are not allowed. On-site cannabis consumption is prohibited at a CGS.
*RECREATIONAL
Technical Details
There are nine types of recreational adult-use cannabis licenses defined in the law including nursery, cultivation, processing, distribution, delivery, retail dispensary, on-site consumption, cooperatives, and microbusiness. All standard applications have a $1,000 non-refundable application fee[102]; fees are reduced by half for equity applicants[103]. Licenses are valid for two years after award[104].
Applications for a new license will only be accepted within the designated application window, which the CCB will announce at least one month in advance[105]. The OCM currently plans to release instructions for the adult-use application in September, and plans to start accepting applications for review in October[106]. All dispensary and on-site consumption licensees are required to notify the municipality where they plan to operate of their intent at least 30 days before submitting an application, although not more than 270 days in advance[107]. The CCB may prioritize applications based on region, license type, equity status, or other criteria.
A specific limit to the number of licenses has not yet been announced. However, the law does authorize the CCB to cap the amount of licenses issued at any point. Additionally, the law dictates that at least 50% of licenses issued must be awarded to equity applicants. As of the July 19th OCM meeting there have been 463 retail licenses issued. This should logically lead to a cap of general adult use recreational dispensary licenses around 400, though this is subject to change and is subject to additional regulatory restrictions. With only 17 operational dispensaries[108], less than 5% of awardees have begun regulated retail sales so far. To keep the balance of active dispensaries within the 50:50 equity ratio, this may further limit the number of recreational adult use licenses initially available this fall.
Nurseries will produce and distribute[109] seedlings, clones, tissue cultures, and cannabis seeds. Nurseries can be outdoor, indoor, or mixed light, though the type of nursery must be specified at the time of application. Indoor and mixed-light nurseries are limited to 10,000 feet[110] of nursery area, and outdoor nurseries can expand up to 100,000 square feet. Nurseries can sell cannabis to other nurseries, or to a cultivator, cooperative, microbusiness, ROND, or ROD; when at-home cultivation is permitted in New York, nurseries will also be allowed to sell to standard retail dispensaries[111]. Nursery licenses can be dually awarded to cultivator, cooperative, microbusiness, ROND, or ROD licensees[112], but never to a standard retail dispensary or an on-site consumption licensee. Biennial license fees for a nursery are $750 for outdoor, $2,000 for indoor, or $1,000 for mixed light.
Cultivation licenses have 5 tiers, each based on canopy square footage. For indoor, outdoor, or mixed light cultivators tier 1 begins with a canopy of less than 5,000 square feet; tier 2 operators can cultivate a canopy up to 12,500 square feet; tier 3 allows a canopy between 12,500 to 25,000 square feet; tier 4 is at least 25,000 square feet but not exceeding 50,000 square feet; tier 5 is the largest and allows between 50,000 and 100,000 square feet of canopy space[113]. Different canopy restrictions are in place for combination cultivators. The tier and type of lighting (indoor, mixed light, outdoor, or a combination of outdoor with mixed light) for the proposed cultivation must be described in the application. Cultivators will purchase their initial cannabis supply from licensed nurseries. Cultivator licensees can obtain a nursery or processor license while continuing their cultivation operations, but cannot be a true party of interest in more than one concurrent cultivation license. License fees increase as the space allowed increases; the outdoor tier 1 license costs $1,000 + $150 per 500 square feet of canopy, and the mixed light tier 5 license costs $70,000 +$1,400 per 500 square feet of canopy.
Businesses operating with a processor license are permitted to extract, blend, and infuse cannabis products. For businesses that are only processing cannabis for white label agreements the biennial license fee is $2,000, unless the business also has a tier 1 or tier 2 cultivation license, in which case the fee is reduced to $500. For processors that intend to infuse and blend products, the biennial license fee is also $2,000. Businesses that plan to perform extractions in addition to infusions and blending have a biennial licensing fee of $7,000.
Microbusiness licensees will be permitted to cultivate cannabis, with canopy space restrictions[114] based on type of light used, distribute cannabis, and to conduct processing activities including extraction[115], blending, and infusion; they may also be permitted to operate a retail point of sale or consumption facility. Annual production limits are in place, unless all cannabis inputs are created by the microbusiness[116]. All planned activities must be described in the application. The biennial licensing fee is $4,500. No person can be a true party of interest for more than one microbusiness.
Cooperative or Collective licenses are also available, where multiple residents of New York create an LLC, collective, or cooperative under NYS Cooperative Corporation Law[117] that operates according to the seven cooperative principles[118] of the International Cooperative Alliance. Adult-use co-ops can cultivate, process, and distribute cannabis to on-site consumption sites, dispensaries, or RODs. All members of the co-op are true parties of interest in the business. No member of the co-op can have a direct or indirect interest in any other adult-use cannabis license in the state of New York, including another co-op. Each application for an adult-use cooperative must describe the types of activities that will take place, and the number of members in the co-op, since the canopy square footage permitted is based on the number of members[119]. The licensing fee structure is based on the cultivated canopy size and type of light used, though co-ops interested in exclusively processing have a license fee of $5,000 per location. Co-ops and collectives can operate an unlimited number of cultivation or processing premises, as paid for and approved by the CCB.
Distributor licenses are stand alone licenses in the supply tier that allow a business to purchase tested and packaged cannabis products from a licensed processor, microbusiness, co-op, ROD, or ROND, and then sell those products to a licensed adult-use retail dispensary, on-site consumption licensee, or a ROD. Interestingly, a distributor can be a true party of interest in a cultivator, processor, co-op, ROD, or other distributor license, and while they cannot be a true party of interest for any microbusiness, they can be a passive investor for an unlimited number of microbusinesses[120].
Retail licensees are permitted to purchase cannabis and related products from licensed cultivators, processors, RODs, RONDs, distributors, and co-ops, and further permitted to sell these products to adult use cannabis consumers. Sales can take place via a drive-thru service window or a pre-order pick up lane, with OCM approval. Retail dispensaries may also operate a limited retail consumption facility, after CCB approval[121]. Retail dispensaries have a $7,000 annual licensing fee; the addition of a limited retail consumption facility brings the fee to $10,000.
Delivery licenses are part of the retail tier and are only available to businesses that also have a retail license. The delivery license does not allow the sale or purchase of cannabis in and of itself. Deliveries are only intended for use in localities that have refused to allow physical cannabis dispensaries. Deliveries are allowed by motor vehicle, foot, bike, or public transit. A delivery license has a biennial licensing fee of $4,500.
On-site consumption licenses are also available, which allows patrons to consume cannabis via inhalation, vaping, ingestion, application, or other uses. Adult-use cannabis, medical cannabis, and CBD hemp products are all permitted at consumption facilities. Limited retail consumption facility licenses are only available as an add-on license for dispensary licensees or microbusinesses that conduct retail operations. Limited retail consumption facilities do not have a point of sale, and are always located inside of a dispensary where products can be purchased. On-site consumption can also be temporarily approved at a dispensary, ROD, or microbusiness, for a specific event[122], in which case it is referred to as an exception area for consumption. Details about the event are required at the time of application, which should be submitted at least 30 days in advance.
General Rules
Home cultivation of adult-use cannabis is not yet allowed in New York. The OCM is required to issue regulations related to home cultivation of cannabis within 18 months of the first adult-use retail sale. The OCM has stated that when home cultivation is permitted, that adults over the age of 21 can have three mature and three immature plants in their home. Cannabis plants must be kept in a secure place that is not accessible to any person under 21. No more than six mature plants can be in any house, regardless of how many adults live there. Home cultivated cannabis is only intended for personal use and cannot be sold to anyone. Local municipalities may enact and enforce regulations relating to home cultivation of cannabis provided, although no municipality can completely ban or prohibit home cultivation. For public safety, it will never be permitted to make hash oil or other cannabis concentrates using substances like butane, propane, or alcohol with home grown cannabis.
Cannabis flower and cannabis value-added products are both available to the adult-use market. Allowable cannabis products include topicals, edibles, capsules, beverages, tablets, tinctures, baked goods, gummies, chocolates, vaporization cartridges, single-use vaporization pens, shatters, waxes, resin, and other cannabis concentrates[123]. All products must be thoroughly tested, labeled, and properly packaged prior to sale. All legal cannabis products sold in New York will include the universal cannabis symbol, in the manner strictly prescribed by the OCM[124].
Public and private cannabis events are permitted, and cannabis cultivators, microbusinesses, RODs, and standard retail dispensaries can partake. Any of these licensees can partner and host an event at their licensed premises, with prior authorization from the CCB or the OCM. All event requests must be submitted at least 30 days before the event is scheduled to start[125] with a non-refundable $50 application fee. Upon approval, an additional event fee is due of $100 for a one day event, plus $50 for each subsequent day. If a large event is planned, the OCM may create additional proportional fee schedules.
The owners, true parties of interest, passive investors, and any management service providers of a supply tier business cannot have any interest in a license of a retail tier business, and vice versa; all licensees must disclose all related individuals and entities and notify the Office of any changes therein. Applicants with an interest in such a business, no matter how small that interest is, will not be approved. No one person or entity can hold true interest in more than one cultivator license, and only a passive investor can hold true interest in more than one processor license. No more than three retail dispensary licenses may be awarded per person.
True parties of interest[126] include[127] the applicant or licensee’s sole proprietor, partner (whether limited or general), member, manager, president, vice president, secretary, treasurer, officer, board member, trustee, director, or any person with an equivalent title to each of the foregoing; a stockholder of the applicant or licensee, other than a person owning 5% or less in the aggregate of a publicly traded company; each person that makes up the ownership structure of each level of ownership for an applicant or licensee that has a multilevel ownership structure; any person with a right to receive some or all of the revenue, gross profit, or net profit from the licensed entity during any full or partial calendar or fiscal year; any person with a financial interest in the applicant or licensee; each person that has authority to or exercises control over the applicant or licensee, with control defined[128] as the authority to order or direct the management, operation, managers, or policies of the business; any person that has membership rights in the applicant or licensee in accordance with the provisions of any articles of incorporation, bylaws, limited liability corporation agreements, partnership agreements or operating agreement; and any person that assumes responsibility for the debts of the applicant or licensee. Goods and services providers are not considered true parties of interest[129].
Regulations
Several parts of the adult-use cannabis regulations of New York are still under review by the OCM, after the final public comment period closed on July 31st at midnight. Regulations relating to medical cannabis licenses[130], conditional licenses[131], packaging and labeling[132], and laboratories[133], have already been finalized. All conditional licensees must comply with any new adult-use regulations.
No retail dispensary, microbusiness, or RODs are allowed to operate within a 1,000 foot radius of one another prior to December of 2023; in towns with a population of less than 20,000 people this restriction is 2,000 feet[134]. Distance restrictions also require dispensaries to be located at least 200 feet away from churches and 500 feet away or more from schools and public youth facilities. No on-site consumption lounges can be within 500 feet of three or more other on-site consumption lounges. Distances are measured in a straight line from the center of the entrances of each building (i.e. two consumption lounges; or, a dispensary and a church) that are closest to one another; if there is no building, the nearest property line[135] may be used instead. Retail dispensaries cannot operate between 2:00 am – 8:00 am[136]. On-site consumption lounges cannot operate between 4:00 am – 8:00 am[137].
Application Requirements
All owners and true parties of interest must be identified[138] for each application, regardless of license type. Significant financial details are required, in addition to personal information[139] such as place of residency, employment, and previous conviction history[140]. Of course, all information presented in an application should be presented honestly[141] and with full disclosures.
The proposed premises[142] should be described in the application, along with the related municipal approval. Required details include the street name and number, GPS coordinates, architectural drawings, floor plans, proof of ability to obtain sufficient insurance, and whether the property is owned by the applicant or not. Additional details could include perimeter security, entrances and exits, canopy area, and a description of activities in each area. All nursery applicants must have a Nursery Grower Certificate of Registration from the NYS Department of Agriculture[143] before licensure by the CCB. All processors must maintain a Good Manufacturing Practice certification[144]. Finding a location that is properly zoned[145] with local approval[146] can be extremely difficult for cannabis businesses. A provisional license may be awarded to applicants that meet all requirements for licensure other than a finalized location[147],[148]. This license gives applicants one year to find a suitable property and submit it for final approval to the CCB. No cannabis related activities are allowed during this time.
Specific instructions for the adult-use license application should be available to the public in September. All applicants must submit an Energy and Environmental Plan[149], which details water usage, air quality, and sustainable packaging plans of the business. Additional materials that are likely to be required include a recall plan; odor control and mitigation plans based on the size and function of each proposed facility; an employee handbook and training manual that describes each role and the responsibilities therein, and that educates employees on internal policies and procedures including emergency safety procedures; security and surveillance plans; a diversion prevention plan; quality control and quality assurance plans; employee training plans; and recordkeeping plans. Cultivation licensees will likely have additional documentation requirements related to proposed lighting and soil plans.
If an application does not meet all regulatory requirements, the OCM may reject the application for cure[150],[151]. In this case, applicants can reapply as soon as the specific deficiency is rectified.
Tips for Winning a Cannabis License in New York
Read All Relevant Regulations, Statutes, and Ordinances
Here at Cannabis Consultants Group, we become elated when new or proposed regulations are released, and we immediately dive in and debate their intent. Not everyone feels a similar excitement in this undertaking, but understanding the regulations that you are obligated to follow as a cannabis business operator is a vital first step.
MRTA is 128 pages[152] and has a very broad view of the cannabis program, including explanations of the governing entities. MRTA created the Cannabis Law. The Cannabis Law has an additional 139 sections that describe the CCB, social equity, and the actions authorized for licensed medical cannabis, adult-use cannabis, and CBD hemp operators. Interestingly, the title of MRTA refers to “marihuana” but the regulatory language throughout almost exclusively uses the term “cannabis”.
The current proposed regulations from the CCB regarding adult-use cannabis contain 344 pages of content with more than 25 pages of definitions. There are an additional 36 pages specific to packaging and labeling requirements, and 62 pages related to laboratories and required testing. Questions can be asked of the OCM by emailing info@ocm.ny.gov.
Many municipalities have additional regulations specific to cannabis operations, which should be read and understood. An official downloadable list of localities that have decided to prohibit cannabis businesses can be found on the OCM local government website[153]. The City of Ithaca has created a cannabis specific page, and provides answers to frequently asked questions[154],[155]. The City of Binghamton has a cannabis business zoning map[156] available on their website, which includes zoning specifically for on-site consumption facilities; legal recreational cannabis sales have already begun in Binghamton[157].
Attend All Regulatory Body Meetings
The CCB and CAB each have meetings that are open to the public and broadcast online. The most recent CCB meeting was on July 19th, 2023. Future meeting announcements, links to watch meetings live, and past meeting minutes and agendas are all available online[158]. The most recent CAB meeting was on June 13th, 2023; details are available online[159].
Local areas or cities may also have relevant meetings about cannabis regulations. For instance, the City of Albany has its own Cannabis Advisory Committee[160], which holds meetings, conducts surveys[161], and has a public texting service for comments related to regulations.
Assemble a Team
A key component of any cannabis business application is proving the applicant’s ability and capacity[162] to successfully conduct operations[163]. While entrepreneurs often want to wear all of the hats at once, the OCM is looking for businesses that will create local job opportunities within equitable workplace environments[164]. A robust team can bring new ideas and perspectives to the table, help to identify and mitigate risks, increase business efficiency, and enhance the customer experience. Attorneys, consultants, executive officers, an employee in charge, and other essential personnel should all be considered as additions to your team prior to application submission.
Attorneys and consultants can help you to understand the laws that apply to your business, draft contracts and other legal documents, and may introduce you to potential partners, investors, or vendors from their network. Common executive teams in the cannabis industry include a Chief Executive Officer to guide the overall direction of the business; a Chief Financial Officer for financial management, accounting system set up, and tax filing; a Chief Compliance Officer to monitor and interpret legal and regulatory changes, and conduct compliance audits of documentation and regular operations; and a Chief Operations Officer responsible for the day-to-day operations of the company, including manufacturing, sales, marketing, and supervision of managerial staff. While additional roles can be added to the c-suite, hiring four distinct individuals specifically suited for each of these positions will create a solid business foundation.
A required role for all cannabis retail dispensaries in New York is an Employee in Charge. The Employee in Charge is considered a managerial position within each dispensary, and the individual must be over 21 years of age. They are responsible for the proper conduct of the employees of the retail dispensary; immediate supervision and management of the retail dispensary during hours of operation; opening and closing of the facility; turning away any individuals from entering the dispensary who present a risk; inventory and delivery acceptance; maintenance of files subject to audit or inspection by the Office; employee training and compliance with state and local laws and regulations; maintaining an up-to-date retail dispensary staffing plan; notifying the Office of the termination of an employee for diversion of cannabis product or theft of currency; notifying the Office of any change of information required to be reported to the Office; and any other activity determined by the Office.
With a significant focus on product and premises security and safety, hiring a Security Director or negotiating a conditional contract with a licensed security team prior to application is very common. Additional positions to consider filling are license specific, such as a Cultivation Director to choose cultivars, define a planting and harvest schedule, and create IPM solutions; or a Processing Director, to oversee the creation of new formulas, quality control, and Good Manufacturing Practices. A Diversity and Inclusion Director, Community Engagement Manager, or similar role will likely be viewed positively by the OCM, given their overall emphasis on social equity.
Conclusion
The most recent proposed regulations are now under review by the OCM, and assuming that there are no substantial changes from the most recent public comment period, these regulations can be finalized in early September, with application details available shortly thereafter. If applications are staggered by license type, cultivators will likely be first, but the OCM has indicated that the October application will be open to cultivator, processor, distributor, microbusiness, and retail licensing applications. Application windows for conditional cultivators was 60 days, and 30 days for conditional retailers; a similar timeframe is expected for standard license applications, though the OCM could choose another timeframe or to accept applications on a rolling basis. Review of applications could take one to three months, and there may be additional time for the curing of deficient applications. Official license awards for standard licensees could happen in early 2024. Application preparation should start now, if you want to win. The process is complex – contact Cannabis Consultants Group for a consultation.
This article details everything you need to know to win a cannabis license in Maryland, including the history of legalization in the state, regulations, political environment, and future cannabis business licensing opportunities. Citizens of Maryland voted to legalize recreational cannabis in November of 2022, and many medical cannabis operators in the state made the transition to include recreational sales as of July 1st, 2023. Now, there is an active application round for additional recreational cannabis licenses, exclusive to social equity-owned businesses, with a limited number of standard- and micro-licenses for cultivators, processors, and dispensaries available. An additional recreational license application round will be held in the spring of 2024, and will include consumption lounge licenses.
Maryland Cannabis Decriminalization
History
1970
Rules set forth by Congress in the Controlled Substances Act[1] label cannabis or “marihuana” as a Schedule I substance, with no currently accepted medical use and a high potential for abuse. Maryland courts have largely abided by this Act since its inception.
1988
Baltimore Mayor Kurt Schmoke delivered an impassioned speech in favor of drug decriminalization at the annual U.S. Conference of Mayors, and later provided similar testimony to the House Select Committee on Narcotics Abuse and Control[2]. Congressman Charles Rangel said this opposition to the War on Drugs made Schmoke “the most dangerous man in America[3]” at the time. Despite naysayers at every level, including in the Reagan and H.W. Bush administrations,[4] Mayor Schmoke continued to support cannabis decriminalization over three concurrent terms, and successfully started several community drug rehabilitation programs.
2000
A four year pilot program for industrial hemp cultivation overseen by the Department of Agriculture began on July 1, 2000. The program was introduced in House Bill 1250, sponsored by Delegates Davis, Guns, Morhaim, and Baldwin[5], during the 2000 regular legislative session; the bill passed the Maryland House of Delegates on March 31st with a 128-8 vote, unanimously passed the Maryland Senate on April 2nd, and was signed into law by Governor Glendening on May 18th.
2003
Governor Ehrlich signed a bill that lessened fines for seriously ill individuals that use cannabis to relieve their pain and other symptoms, with a maximum of $100. Ehrlich was the first Republican Governor to sign legislation in support of medical marijuana, and faced significant opposition from his party and the presidential administration[6]. However, this did not create a retail framework for medical cannabis, nor did it protect individuals from arrest.
2010
Maryland has the fourth highest arrest rate in the nation for cannabis related crimes[7].
2013
Governor O’Malley signed into law[8] a medical marijuana program for Maryland in May. This allowed for academic medical centers to provide monitored care of medical marijuana patients for research as an investigational use “program” with oversight from the federal Department of Health and Human Services.
2014
House Bill 881 created the Natalie M. LaPrade Maryland Medical Cannabis Commission[9] (“the MMCC”) and allowed for the creation of a legal medical cannabis market. Senate Bill 364, proposed by Senators Robert Zirkin and Allan Kittleman and signed into law by Governor O’Malley in April 2014, changed the possession or use of less than 10 grams of marijuana to a civil rather than criminal offense.
2016
The Maryland Medical Cannabis Commission opened applications for cannabis business licenses, and received hundreds of applications. SB 517 changes possession of cannabis paraphernalia and smoking outside from a criminal activity to a civil infraction with fines.
2017
The first medical cannabis retail sales to registered patients occurs in December, and sales total over $1.8 million in the first month[10].
2018
Senator Young introduced Senate Bill 333, related to reducing the impact of 280E on licensed cannabis operators in Maryland. SB333 would create a subtraction modification for certain business expenses related to medical cannabis cultivation, processing, dispensing, and testing. The bill was cross-filed in the house, but stalled after referral to multiple committees. Maryland officials have reintroduced similar bills in each legislative session since and they have faced an identical demise.
2019
A significant decision was made in Pacheco vs State of Maryland[11] in August 2019, when the Court of Appeals decided that the smell of marijuana is not a probable cause for police to search or arrest a person, and withheld that the individual could simultaneously possess less than ten grams of cannabis without due cause to search their person, vehicle, or home.
2019
The Maryland Medical Cannabis Commission opened applications for cannabis business licenses, and received interest from hundreds of businesses[12]. Additionally, Governor Hogan signed HB 17[13] into law, legislation authorizing the manufacturing and medical sale of cannabis edible products.
2020
The Maryland Medical Cannabis Commission developed COVID emergency measures[14] that allowed licensed retailers to deliver to registered patients, and permitted curbside pickup and the use of telehealth for patient reenrollment.
2021
Delegate Jazz Lewis introduced House Bill 32 for adult-use legalization and expungement of certain prior cannabis convictions. The Maryland Center on Economic Policy created an official statement of support[15] for HB32 and testified accordingly in front of the Judiciary Committee. Senate Bill 708, which also sought adult-use legalization, was introduced in the same session by Senator Feldman. Maryland House of Delegates Speaker Adrienne Jones decided that the outcome of both bills HB32 and SB708 should be determined by voters via a referendum.
2022
House Delegate and Chairman of the Judiciary Committee Luke Clippinger introduced HB1 to allow citizen voters to decide the fate of cannabis legalization[16]. HB 837 was also proposed[17] by Delegate Clippinger and passed by the Assembly, which established the Cannabis Public Health Advisory Council and a Cannabis Public Health Fund. The bill further explicitly requires data collection and studies on cannabis use, impaired driving, and other health and safety issues. The voters of Maryland passed the referendum in November, with 67.2% in favor[18], to amend the state Constitution and allow cannabis use for all adults over the age of 21.
2023
The Cannabis Reform Act[19] was signed into law on May 3rd. This reform allows adults over 21 to possess up to 1.5 ounces of cannabis flower, 12 grams of vape products, or 750 mg THC in edible form, and each household may grow up to two plants for personal use. Possession above these amounts can result in a fine, and furthermore, possession of over 2.5 ounces of flower is criminalized. The Cannabis Reform Act also created processes for the automatic expungement of past cannabis possession convictions, and mechanisms for resentencing for the currently incarcerated. The Maryland General Assembly established rules for the recreational cannabis market, and created the Maryland Cannabis Administration to oversee the implementation, via HB 556[20] and SB 516. Governor Wes Moore signed HB232[21] into law effective July 1st, which protects parents who lawfully use cannabis from unjustified child neglect penalties.
2024
Applications for recreational cannabis business licenses will be accepted by the Maryland Cannabis Administration around May 1.
Maryland Cannabis Regulatory Entities
Individuals and groups that create laws, regulations, and rules related to cannabis include the state General Assembly and Governor, the Maryland Medical Cannabis Commission, Cannabis Public Health Advisory Board, and the Maryland Cannabis Administration. The Office of Social Equity and the Alcohol, Tobacco, and Cannabis Commission also have roles in regulation.
The General Assembly is favorable overall to cannabis reform, and allowed voters to decide the next steps for recreational cannabis. The legislature agreed in 2022 to replace all references to the term “marijuana” with “cannabis” for consistency[22]. Former Governor Larry Hogan had hesitations about cannabis, but allowed cannabis legalization bills to pass into law without his signature, nor veto. Current Governor Wes Moore has publicly stated his support for social equity measures within the cannabis industry[23]. The Governor has over $1 million worth of stock[24] in Green Thumb Industries, an active cannabis operator in Maryland and other states.
The Maryland Medical Cannabis Commission (“MMCC”) was established in 2014 to develop policies, procedures, and regulations for a safe and effective medical cannabis program. Under this program, licensed medical cannabis sales of tested products for qualified patients began on December 1, 2017. The MMCC created a home grow program for qualified patients starting in 2022 to grow cannabis plants for personal use, based on research[25] from best practices implemented in other states. Staff from the MMCC have transitioned to be a part of the Maryland Cannabis Administration, upon its inception in 2023. This is meant to provide a feeling of continuity for businesses and patients in the medical program. New regulations governing health, safety, and security of cannabis are considered supplemental to the existing medical cannabis program regulations, which will continue to be enforced.
The Cannabis Public Health Advisory Council was created by HB837 in 2022[26]. The Council has conducted studies on the public health impact of cannabis legalization in Maryland, and provides ongoing public health recommendations regarding cannabis and educational programs, advertising requirements, training for health care providers, quality control requirements, school-based prevention initiatives, youth behavioral outcomes, and other cannabis data collection. The Maryland Department of Health has a significant supportive role in the operational execution of the Council[27],[28].
The Department of Health oversees the Cannabis Public Health Fund to support Council duties and to address the community health effects associated with the legalization of adult-use cannabis. The Council consists of members appointed by the Governor[29] who serve four year terms, including a cannabis laboratory representative; a public health professional with cannabis experience; an individual with experience in health or social equity; an academic researcher with expertise in cannabis law and policy; an expert in cannabis use disorder; a substance use disorder treatment and recovery health care specialist; a pharmacist licensed in Maryland; an additional health care provider, with general experience in cannabis; a representative from the Governor’s Office of Crime Prevention, Youth, and Victim Services; and one representative from a historically black college or university; and, individuals that serve concurrently in public service positions, specifically the Secretary of the State of Maryland; the Deputy Secretary for Behavioral Health; the Secretary of Agriculture, or their designee; the executive director of the MMCC, or their designee; and, the state superintendent of schools, or their designee[30]. Members of the Council are not compensated, though travel may be reimbursed.
The Maryland Cannabis Administration (“MCA”) was established in 2023 as an independent agency to oversee all cannabis related licensing, registration, inspection, and testing, and to provide relevant access and educational information to patients, adult consumers, caregivers, growers, pharmacists, processors, dispensaries, testing laboratories, and other interested individuals. The stated vision of the Administration is to collaborate with stakeholders in fostering a high-quality and inclusive cannabis industry that serves as a national model. The MCA has a full time staff of 100+ people, across nine[31] departments: compliance and regulation; product testing and laboratory compliance; communications; budget and procurement; information technology; human resources; policy and government affairs; research and education; and medical cannabis registration. The MCA is currently accepting applications for recreational cannabis business licenses[32].
Medical Cannabis
Rules and Regulations
The MMCC was created in 2014 to create and oversee the medical cannabis market. There is a regulatory limit of 94 dispensary licenses allowed across the state, with up to two per Senate district. The MMCC has held multiple licensing rounds for interested applicants. The regulations for medical cannabis operations are nested within the Department of Health laws.
Previous Applications
The first application round for medical cannabis businesses was announced in September 2015. Application materials were due 40 days later, with templates provided by the MMCC. Applications were ranked based on operational readiness, procedural summaries, safety and security factors, production control, business and economic information, and additional details such as proposed products offered. Stage one conditional licenses were awarded within a year. The Commission received over 800 completed applications for prospective businesses. Ultimately, 15 cultivation and processor licenses were awarded, including seven companies that were approved to both cultivate and process cannabis. Lawsuits related to dispensary location fairness and geographic diversity were filed, ultimately resulting in certain businesses that had been denied in the first application round (including national operator Green Thumb Industries) being pre-approved for future licenses.
In 2019, the MMCC held an additional licensing application round for medical cannabis businesses, and once again received intensive interest. Applications were evaluated through a third party, and the MMCC approved final applicant rankings from third party evaluators on September 18, 2019. However, allegations of potential bias or undue influence in the license application review process were immediately voiced by multiple parties. The MMCC paused the license approval process to allow for the allegations to be reviewed. The impartiality of the application review process was investigated by Zuckerman Spaeder, LLP, and found in September 2020 that no preferential treatment was given based on bias or other undue influence[33].
A concurrent investigation from Verity, LLC, focused on the accuracy of disadvantaged ownership claims, which resulted in the denial of multiple top-ranked applications. On October 1, 2020, the MMCC awarded stage one license preapproval for three cultivators and eight processors[34], after receiving and reviewing more than 200 applications. None of the 11 originally issued 2019 licensees were operational within the regulated 12 month time period from provisional award in October 2020. Each asked for an extension, and the MMCC unanimously voted to approve extensions in September 2021.
Current Market
The first medical cannabis sales in Maryland began on December 1, 2017, with 14 cultivators, 12 processors, and nine dispensaries in the state; 550 health-care providers were registered to certify patients as eligible; and 8,500 patients were certified by the Commission to buy medical cannabis. In 2023, there are nearly 20 times as many enrolled patients, and hundreds of licensed businesses.
Licensed medical cannabis operators in good standing were given the option to also sell to recreational consumers beginning on July 1, 2023, for a fee of up to $2 million[35]. All medical cannabis licensees converted to serve both markets[36]. Notably, multi-state operators Ascend, Cannabist (formerly Columbia Care), Curaleaf, Green Thumb Industries, TerrAscend, and Verano collectively account for more than 20% of the current dispensaries in Maryland. At the onset of recreational retail, sales totaled more than $91 million[37] in August compared to $42.7 million in June from medical sales[38].
Medical Cannabis Patients
There are more than 145,000 registered medical cannabis patients in Maryland[39] as of November 1, 2023, fewer than the year-to-date peak of 163,935 in June. Medical cannabis patients in Maryland must reside in the state and be diagnosed with a qualifying condition. Licensed medical cannabis dispensaries can deliver products to existing patients. Minors may participate in the program if they have an adult caregiver, and the caregivers must register with the MMCC prior to working with minor patients. Out-of-state residents can only participate in the medical cannabis program of Maryland if they have an inpatient stay at an accredited medical facility in the state.
Maryland uses an online patient registry, OneStop Portal[40], for initial requests, written physician certifications, and to provide patients with their registration details once approved. New submitted applications and renewals are $25, and the fee is nonrefundable[41]. Conditions that qualify for medical cannabis support include cachexia, anorexia, wasting syndrome, severe or chronic pain, severe nausea, seizures, severe or persistent muscle spasms, glaucoma, post-traumatic stress disorder (PTSD), or other chronic medical conditions that traditional treatments have been ineffective for. For registration, a valid email account is needed, as well as, a social security number, proof of Maryland residency, and government-issued photo ID. The standard certification amount of medical cannabis allowed for purchase in a rolling 30-day cycle is 120 grams of flower or 35 grams of a THC product[42], though it may vary per individual.
There are no employee protections in place for medical cannabis consumers, and employers may take action against any individual testing positive for cannabis for any reason. Additionally, most health insurance providers in Maryland will not cover medical cannabis costs.
Recreational Cannabis
Legalization Vote
In November of 2022, Maryland voters approved legalization of adult use cannabis with a 67.2% majority[43]. This vote amended the Maryland Constitution to authorize the General Assembly to create a regulatory framework “for the use, distribution, possession, regulation, and taxation of cannabis within the state”[44], and enacted House Bill 837. HB 837 created procedures for cannabis related expungements, increased the amount of cannabis that can be legally possessed, founded the Cannabis Public Health Advisory Council, and established three distinct funds for: community reinvestment and repair, which provides money to communities disproportionately impacted by cannabis prohibition and enforcement; business assistance, to increase participation in the cannabis industry by small, minority, or women owned businesses; and a public health fund, to address community effects related to legalization of adult cannabis use, and to monetarily support the Advisory Council mission.
Adult Use Consumption
As of January 1, 2023, adults in Maryland may possess and consume a “personal use amount” of cannabis, up to: 1.5 ounces of cannabis flower, or 12 grams of concentrated cannabis, or edibles that do not exceed 750 mg THC. A criminal penalty still stands for possession of more than 2.5 ounces of cannabis, or for possession of any amount of cannabis on federal property (such as national parks or the Baltimore-Washington Parkway). Smoking cannabis or hemp is not allowed in any public spaces, including bars, sidewalks, parks, or workplaces. For Maryland residents, each household may cultivate up to two cannabis plants, regardless of how many persons over age 21 live together. The plants must be out of public view and inaccessible to minors.
On July 1st, 2023, recreational sales began in Maryland for all adult (21+) consumers, from concurrently licensed medical cannabis operators. Valid government issued ID is required for age and identity verification; individuals can only purchase up to the personal use amount. Recreational consumers[45] are not permitted to purchase concentrated products such as hash or rosin[46],[47], though vape cartridges are available[48]. Cannabis products are subject to a 9% sales tax. Retailers can sell home cultivation products to adult consumers as well as usable cannabis products. Mailing cannabis remains illegal in the United States, even between two decriminalized states, or within a legal state such as Maryland.
Recreational Cannabis Market
The Maryland General Assembly created a regulatory framework for the adult use market in their 2023 regular session, commonly referred to as the Cannabis Reform Act. The Act authorizes the MCA to issue cultivation, processor, dispensary, incubator, and consumption lounge licenses over two licensing rounds. The first licensing round is fall 2023, with all application materials due by December 12th at 5pm, and is exclusive to businesses with at least 65% social equity ownership. The second licensing round will be on or after May 1, 2024.
Standard and micro business dispensary, processor, and cultivator licenses are available for the first licensing round, with important distinctions. Micro licensees in good standing after 24 months of operation may convert to a standard license. Micro dispensaries may only offer delivery, and cannot have a brick and mortar location. Standard dispensaries must be able to accommodate medical patients, with a dedicated patients-only hour or a dedicated medical cannabis service line for all operational hours, and may not offer delivery. All standard dispensaries must therefore have a Clinical Director[49] to oversee the medical cannabis patient services[50]. Medical cannabis sold to qualified patients is exempt from sales and use tax. Micro processors can not process more than 1,000 pounds of cannabis per year, and standard processors must manufacture at least 1,000 pounds of cannabis into usable products per year.
Micro cultivation licensees are permitted up to 10,000 square feet of indoor canopy, or equivalent[51], whereas standard cultivators will operate between 10,000 and 300,000 square feet of indoor canopy. Canopy is defined as the total square footage of space used to produce flowering cannabis plants, and includes each layer of flowering cannabis plants grown on any rack or shelving, and canopy does not include square footage used for mother stock; propagation; immature or nonflowering plants; processing; drying; curing; trimming[52]; storage; offices; hallways; pathways; work areas; or other administrative and nonproduction uses. Cultivators can choose indoor or outdoor canopy, or a hybrid of both. Cultivators and processors are responsible for final product packaging[53], and the state currently uses Metrc for seed-to-sale tracking.
A cannabis incubator space license allows the licensee to host a micro business within their facility. On-site consumption lounge licenses are considered a standard license type, and will not be available until the second application round. Each county and municipality must issue an explicit allowance of consumption establishments before licenses will be permitted. Consumption lounge licensees cannot cultivate cannabis; process cannabis; process cannabis-infused products; or add cannabis to foods or other items sold at the establishment. Any individual or entity with an ownership interest in or control of an on-site consumption lounge cannot have a controlling or ownership interest in any other type of cannabis license.
The maximum number of available licenses per type and per round is dictated by law; the maximum allowable licenses for the first application round (Fall 2023) is 20 standard cultivation licenses, 30 micro cultivation licenses, 40 standard processor licenses, 30 micro processor licenses, 80 standard dispensary licenses, 10 micro dispensary licenses, and 10 licensed incubator spaces. The MCA may offer even fewer licenses in a given round, and reserves the right to deny any application that is not complete in every material detail[54]. If there are more qualified applications than the number of licenses available in a round, all qualified applicants will be placed in a lottery to select the winners. The first application round is reserved for social equity applicants.
Medical Cannabis Conversion to Recreational Market
The Cannabis Reform Act authorized existing licensed medical dispensaries to convert their licenses for dual medical and adult-use sales before July 1. More than 100 businesses[55] have chosen to transition to include recreational sales in their operations, including multi-state operators. Each cannabis dispensary must provide patient-only operating hours, or dedicate a service line exclusively for patients during all operating hours. Maryland does not offer medical cannabis reciprocity, so out of state cannabis patients must shop recreationally, and cannot access patient only hours, patient lines, or medical grade products.
Social Equity
The Cannabis Reform Act created an Office of Social Equity specifically to assist social equity applicants and small, minority, and women-owned businesses with applications and business financing. The legislation has additional measures intended to support social equity, such as exclusive social equity applicant licensing rounds, access to grants, prohibition of application property requirements, and the creation of new license categories that require less capital to operationalize.
To qualify as a social equity applicant in Maryland, you must have lived in a disproportionately impacted area for at least 5 of the past 10 years, defined as an area that had above 150% of the state’s 10-year average for cannabis possession charges; or, attended a public school in a disproportionately impacted area for at least 5 years; or, attended, for at least two years, a 4-year institution of higher education in the State where at least 40% of the individuals who attended the institution are eligible for a Pell grant.
The first round of recreational cannabis business applications from the MCA is exclusively for social equity applicants. The second round of applications will likely have a small number of licenses available for general applicants. To determine how many additional social equity licenses should be awarded in round two of applications the MCA will conduct a study of active operators, in consultation with the Maryland General Assembly; Governor’s Office of Small, Minority, and Women Business Affairs; and the Office of the Maryland Attorney General.
The Cannabis Business Assistance Fund in the Department of Commerce is set up as a nonlapsing fund[56] operated by the Maryland Department of Commerce to provide financial assistance to small, minority, and women-owned businesses entering the adult-use cannabis industry[57]. Currently, expenses for outside assistance and consultation that an individual needs to complete their application can be up to 50% reimbursable through a grant, up to $5,000.
Fall 2023 Application
Critical Application Steps
Complete the MCA interest form and quiz[58] before November 6th, to confirm that all parties understand the application process.
Verify social equity status with Creative Services, Inc (“CSI”) before November 7th[59],[60].
Apply and receive a business registration number from the Maryland Department of Assessments and Taxation.
Submit license application materials by 5pm EST on December 12 through the OneStop portal. All fees must be paid for an application to be considered complete.
Ownership Requirements
For this application round, all businesses must have at least 65% ownership by social equity individuals; multiple individuals can cooperate and co-own a business to total 65%. Individual social equity status must have been verified through a third party portal prior to November 7th, 2023. Anyone that has not verified their social equity status in advance may not apply for more than 35% ownership in this application round. Nearly 900 individuals have been successfully verified as social equity applicants[61].
The Office of Social Equity defined the specific qualifiers of social equity with the identification of Bowie State University, Coppin State University, Morgan State University, University of Baltimore, University of Maryland Eastern Shore, and Washington Adventist University as higher education institutions where at least 40% of the attendees are eligible for a Pell grant; publication of a 19 page list of schools[62] where attendance of more than five years qualifies; and the zip codes[63] that have been disproportionately impacted by cannabis charges for the five year residency requirement.
Individuals from similarly impacted areas from other states can also qualify as social equity applicants for this licensing round – technically. However, clear guidance has been difficult to find, and the MCA believes that the burden for proof of qualifications is the sole responsibility of the applicant, not the Administration. Reportedly, multiple out-of-state applicants that qualify in their home state as social equity applicants have failed to verify in Maryland, which may result in related lawsuits. Any lawsuits raised against the MCA may increase the time before additional license application rounds.
Technical Details
An individual may be associated with one application per license type, and up to two total applications in a given round. Ownership interest forms and background check investigations are required, along with a business capitalization table totalling 100% that includes explicit disclosures of any other entities associated with any ownership shares. Additionally, each business must meet social equity requirements, register with the Maryland Department of Assessments and Taxation, and pay a nonrefundable fee to the MCA. Fees are $5,000 for standard business applications, and $1,000 for microbusiness applicants.
A person or entity may not have control[64] of or ownership interest in more than one cannabis grower license (standard or micro); and one cannabis processor license (standard or micro); and four cannabis dispensary licenses (standard or micro)[65]. Any individual or entity with an ownership interest in or control of an on-site consumption lounge can not have a controlling or ownership interest in any other type of cannabis license.
The licenses available in this round are 16 standard cultivation licenses, 32 standard processor licenses, 75 standard dispensary licenses, 24 micro cultivation licenses, 24 micro processor licenses, and 8 micro dispensary licenses. These licenses will be further divided by counties and regions, based on the historic impact of the War on Drugs in each community. Applicants do not need to have a property lease or site control. However, each license is tied to the area of intended operation declared on the application.
Standard Dispensary licenses will be dispersed by county
Processor, cultivator, and micro dispensary licenses will be distributed by region; the western region includes Allegany, Carroll, Frederick, Garrett, Montgomery, and Washington; the southern region includes Anne Arundel, Calvert, Charles, Prince George’s, and St. Mary’s; the central region includes Baltimore, Baltimore City, Cecil, Harford, and Howard; and the eastern region includes Caroline, Dorchester, Kent, Queen Anne’s, Somerset, Talbot, Wicomico, and Worcester. Per region, 4 standard cultivation, 8 standard processor, 6 micro cultivation, 6 micro processor, and 2 micro dispensary licenses will be awarded[66].
All applicants are expected to be familiar with the laws and regulations governing cannabis in Maryland. To confirm that all parties understand the application process, each individual must complete an MCA Cannabis Business Interest Form and Quiz before November 6th. More than 3,000 people expressed interest through completion of this form.[67] All interested parties must complete their social equity verification process before November 7th to move forward with the application. For verification, all interested parties must submit the appropriate paperwork through a third party portal, accessed via a unique link sent in an email upon completion of the MCA Interest Form and Quiz.
Each application must include redacted and unredacted copies of an operational plan, business plan, and diversity plan. The MCA has specific templates and page restrictions for all materials, and all responses must be in 12-point Times New Roman font. The operational plan template “Attachment A” has nine prompts with short response boxes to confirm that regulatory compliant documentation will be created by the applicant regarding workplace safety, emergency protocols, sanitary practices, storage procedures, security protocols, and additional safety procedures[68] upon conditional license award.
The business plan template “Attachment B”[69] has space to describe funding intentions and timeline; proposed premises and zoning compliance actions; lists of all principal officers; and an overview of business success factors, including past applicant experience; the maximum allowable space is 11 total pages. The diversity plan template “Attachment C” provides one page each to explain the business diversity goals, related action plan, how the business defines diverse participants, and overall outreach plans[70]. Application materials must be submitted in the OneStop portal during the “application period” beginning on November 13th and ending promptly at 5pm on December 12th for consideration. The portal will require the applicant to attest to the accuracy of materials, give consent to background investigations, and all required attachments to be uploaded, before submission can occur[71]. All submissions are immediately considered property of the MCA and will not be returned[72].
If applicants do not meet the minimum requirements of the lottery, they will be informed by the MCA, then given ten days to request a records review, to confirm the insufficiency. Further grounds for denial or disqualification include incomplete application sections, duplicate applications, ownership conflicts, lies, misrepresentations, alteration of application templates, omissions, or a failure to turn an application in on time (5pm on Tuesday, December 12th, 2023).
The MCA will notify applicants of their individual outcome on or before January 1, 2024. Applicants selected from the lottery can receive a conditional license[73], valid for 18 months, to identify a location and establish control; submit additional verification materials, as needed; raise funds; obtain zoning and planning approval; obtain local approval; and pass all health, safety, and security inspections, including inspections from the MCA. Ownership or control cannot be changed during conditional licensure. Conditional licensees may not begin cultivation, manufacturing, selling, or possessing of cannabis products until given final approval and a license award from the Administration.
Lack of timely public awareness for business registration requirements may lead to legal battles.
The MCA[74] advised Maryland residents against certain partnership opportunity advertisements. The MCA regulations[75] related to the application process and issuance of licenses have set the expectation that applicants could complete their business registration after the lottery process, if awarded a conditional license. However, the general instructions for application released by the MCA[76] in October states that an application must include a registration number from the State Department of Assessments and Taxation; this registration number must match the application information and be specific to the prospective cannabis business licensee.
Conclusion
In addition to carefully reviewing this living document, understanding the statutes, regulations, and ordinances governing the location and activity of cannabis businesses is essential to becoming operational and subsequently maintaining compliance in the Old Line State. Winning a cannabis license in Maryland is challenging, but not impossible with the right preparation and commitment. For industry-insider support, application development, team building, and connection to potential partners and investors, Contact Cannabis Consultants Group.
This article provides all the details you need to know to win a cannabis license in Ohio. A historical timeline of cannabis legalization is included, along with details of the current political environment related to cannabis in the state. An explanation of the medical cannabis market includes technical details of each application round, general rules regarding medical cannabis and patients, legal battles related to social equity, and how medical operators will expand into the adult use market. Finally, opportunities within the recreational cannabis market of Ohio are described in depth.
Historical Timeline of Cannabis in Ohio
1860
The Ohio State Medical Society held a clinical conference related to cannabis in 1860 and reported on medical successes of cannabis for multiple diagnoses[1],[2].
1975
Governor Rhodes signed into law House Bill 300, in general alignment with the federal Controlled Substance Act, though HB 300 decriminalized possession of cannabis if less than 100 grams.
1980
The 113th General Assembly passed Senate Bill 185[3] to create a four-year controlled substances therapeutic research program operated by the Ohio Department of Health to study the therapeutic uses of marihuana.
1990
Multiple increases of fines and other penalties for drug related offenses passed the General Assembly, including HB 215, related to the sale or possession of controlled substances at or within 1,000 feet of a school, and SB 258.
2015
Ohio citizens voted 63% in opposition[4] to Issue 3 on the November ballot, which sought to legalize recreational marijuana statewide through constitutional amendment[5]. The measure focused strongly on monopolistic control of the market and did not have support of some cannabis advocacy groups. Also on the November ballot was Issue 2, which the legislature created to ban special-interest groups from creating constitutional amendments for financial gain[6]. Issue 2 passed with 51% of votes cast in favor.
2016
On September 8, 2016, House Bill 523 legalized medical marijuana in Ohio. This bill established the basic framework for Ohio’s Medical Marijuana Control Program. Smoking cannabis and home cultivation for medical patients are not included in the new law.
2018
The Ohio Board of Pharmacy issued provisional licenses for cultivators, processors, testing laboratories, and retailers of medical marijuana. Multi-state operators Green Thumb Industries[7] and GreenLeaf Apothecaries were each awarded the maximum allowable of five dispensary licenses.
2019
First medical cannabis sales began on January 16th from CY+ in Wintersville, The Forest Sandusky in Sandusky, Ohio Valley Natural Relief in Wintersville, and The Botanist (operated by GreenLeaf[8]) in Canton.
Image: Line Outside of CY+ Dispensary in Wintersville on the First Day of Medical Marijuana Sales. Source: AP News.
2023
November 2023, voters said yes to adult-use cannabis legalization in the state with a 57% majority. The initiative will go into effect on December 7th.
Political Environment for Cannabis Licensees and Stakeholders in Ohio
Previous Administration
Elected officials in Ohio have given begrudging support of the medical cannabis program since its inception. The 2016 Medical Marijuana Control Program was passed with bipartisan support after pressure from Ohio citizens. Legalization of recreational cannabis for adult use has not been historically supported.
Current Administration
Cannabis reform remains a contentious issue within the Ohio General Assembly, despite the November 2023 voter majority for recreational cannabis legalization. The state legislature can amend the initiated statute at any time, which could impact the effective date and related provisions. Some officials proposed alterations to the language of the Act before its early December implementation, including House Speaker Jason Stephens and Senate President Matt Huffman, with the stated assumption that voters didn’t fully comprehend the issue they passed[9],[10]. Other elected officials, such as Representative Casey Weinstein, Representative Jamie Callender, and Senator William DeMora, have emphasized the importance of respecting the intent of the voter initiative[11],[12]. Senator Sherrod Brown and Representative Dave Joyce each shared publicly that they cast their personal ballots in favor of cannabis legalization[13].
Governor Mike DeWine openly opposed the ballot measure, and said it “would be a real mistake for us to have recreational marijuana” in Ohio[14], but since voters passed the issue, has stated that he “respects the peoples clear choice to have legal marijuana”[15] in Ohio and will make sure that happens. The Governor has requested the legislature carefully consider safe and respectful implementation, especially through the prevention of accidental edible consumption, advertising restrictions, and limiting the number of people under the influence while driving, and has recently advocated for the elimination of criminal penalties for cannabis possession[16].
On December 4th, just days before a voter initiative for adult use cannabis legalization would come into effect, the Ohio Senate General Government Committee added language to HB 86, a bill originally created to make minor changes to alcohol regulations[17], that sought to disallow home cultivation and drastically change tax revenue allocation while creating new product potency limits and reducing the number of potential dispensary licenses[18]. HB 86 was then processed as an emergency regulation so that it would take immediate effect and circumvent the voter approved initiative, but required a two-thirds majority vote to pass and a signature from Governor DeWine. Thousands of Ohio constituents immediately called and emailed representatives in protest of these changes. On December 6th, after increased pressure from the public and advocate testimonies to committees, the Senate passed a version of HB 86 that would retain home cultivation, provide automatic expungements of prior cannabis convictions, and expedite the process for adults to purchase products from currently licensed dispensaries. Since the bill still requires concurrence from the House, the voter initiated measure went into effect on December 7th. Additional reform is still likely to occur. Representative Gary Click has independently proposed HB 341, which would allow municipalities to ban home grow and cannabis businesses and provide 19% of cannabis tax revenue to law enforcement[19], and Representative Cindy Abrams has introduced HB 326 to use a portion of the tax revenue to fund peace officer training[20], with a stated goal of $40 million annually[21]. The Court of Common Pleas of Franklin County[22] will hear any challenges related to the Cannabis Control Act implementation or its adopted rules.
Image: Governor DeWine at a December 6 Press Conference Discussing Recreational Marijuana. Source: Ohio WKYC Channel 3 News.
Cannabis Regulatory Bodies
The State of Ohio Board of Pharmacy, the State Medical Board of Ohio, and the Ohio Department of Commerce collectively oversee the Medical Marijuana Control Program of Ohio (“MMCP”). Since the MMCP inception in 2016 the Board of Pharmacy and State Medical Board have been responsible for oversight of dispensaries, dispensary employees, and regulated medical cannabis products, and the Department of Commerce is responsible for licensure of cultivators, processors, and testing laboratories. A newly created Division of Cannabis Control will oversee the adult use cannabis program.
The State of Ohio Board of Pharmacy (“the Board”) is responsible for the licensure of retail dispensaries and of dispensary employees. The Board also issues identification cards for medical cannabis patients and their caregivers, and provides educational resources to promote informed decision-making and safe medication use. The Board manages the patient and caregiver registry, and the Ohio Automated Rx Reporting System (“OARRS”) has been operated by the Board since 2006 with the intent to detect the diversion, abuse, and misuse of controlled substances[23] and is used throughout the MMCP to track all retail sales. All new forms of medical marijuana must be reviewed, approved, and assigned a product identifier by the Board before production or sale.
Image: State of Ohio Board of Pharmacy Logo and Seal. Source: State of Ohio Board of Pharmacy.
The Division of Cannabis Control (“the Division”) has the authority to license, regulate, investigate, and penalize adult use cannabis operators, adult use testing laboratories, and any individuals required to be licensed related to recreational cannabis businesses[24]. The Division was established by the Act to Control and Regulate Adult Use Cannabis[25]. The Division is within the Department of Commerce and will create rules related to recreational cannabis topics, including which forms of cannabis may be sold, required testing, and a seed-to-sale tracking process. The Department of Commerce published a guide for Ohio residents to learn about cannabis legalization and implementation within one day of the vote passing[26].
The Ohio Department of Mental Health and Addiction Services (“MHAS”) works closely with the Division to provide publicly accessible education about addiction issues related to cannabis or other controlled substances. MHAS also administers the cannabis addiction fund, in support of addiction and substance abuse services and to conduct related research. The fund helps cover costs for a statewide toll-free telephone number, operated by MHAS, that Ohio residents can call to obtain help or information about available addiction services. MHAS will prepare an annual report for the Director of Commerce on the specific uses of all funds and their purpose related to cannabis education or treatment services.
Social Equity
Original legislation related to medical marijuana legalization stated that 15% of all medicinal cannabis business licenses be awarded to racial minority applicants. Provisions similar to this are common in states that legalize cannabis, as an attempt to rectify the impact of the War on Drugs. However, the equity provision in Ohio was deemed unconstitutional[27] in 2018 because it specified race as the only social equity qualifier, creating a “racial quota” that violated the Equal Protection Clause of the Fourteenth Amendment and the Ohio state constitution. This ruling came on August 24, 2018, months after the first round of licenses were issued, 16% of which were awarded to minority-identified applicants.
PharmaCann Ohio LLC and Greenleaf Gardens LLC each filed cases against the Ohio Board of Pharmacy arguing that their license denials were unfair. PharmaCann was awarded a license in May 2018[28] after a scoring error was discovered, and Greenleaf Gardens was awarded a license after the social equity provision was removed. In June of 2019 the Board of Pharmacy alleged that one social equity licensee, Harvest of Ohio, violated regulations with observed operational control performed by a white male. The case outcome was a half million dollar donation by Harvest of Ohio towards the state’s prescription drug reporting database[29] with an explicit agreement that ongoing business operations are led by a diverse team. As of April 2021, the Columbus Dispatch reported that 9 out of 57 active dispensaries in Ohio were equity owned,[30] precisely 15%.
The recently passed Ohio Act to Control and Regulate Adult Use Cannabis instructs the Department of Development to establish a Cannabis Social Equity and Jobs Program (“program”) based on both social and economic disadvantages. The program will create methods for social equity certification and strive to educate potential participants about business opportunities. Financial and technical assistance will be provided to certified individuals through the program. Funds from the program will go towards judicial and criminal justice reform, financial assistance for social equity applicants, and investment in communities most impacted by cannabis criminalization. Additionally, the program will propose policy reform related to the impacts of cannabis law enforcement. All licensed cannabis businesses will be encouraged to implement employment practices to hire and educate specific disadvantaged groups.
Criteria for social equity applicants has been updated since 2018. Eligibility for the program will be based specifically on the wealth of the business and personal wealth of its owners; business location in qualified census tracts; business size; racial minority; personal disadvantage due to color, ethnic origin, gender, or physical disability; disadvantage from long-term residence in an area of high unemployment; and whether the owner or their spouse, child, or parent, have ever been arrested for, convicted of, or adjudicated delinquent for a cannabis related offense prior to December 7th, 2023. Participants in the social equity program will be continually reevaluated for qualification.
Medical Cannabis
Medical Cannabis Patients
Since the Ohio Medical Marijuana Control Program inception, 403,452 medical cannabis patients have registered in Ohio. As of October 30, 2023 there are 178,703 active patients[31] in the MMCP, 6,255 less than the month before. Patients must have a current registration and physician recommendation to be considered active. Registration is valid for one year. Under Ohio law, qualifying conditions for medical cannabis include AIDS, amyotrophic lateral sclerosis, Alzheimer’s disease, cachexia, cancer, chronic traumatic encephalopathy, Crohn’s disease, epilepsy or another seizure disorder, fibromyalgia, glaucoma, hepatitis C, Huntington’s disease, inflammatory bowel disease, irritable bowel syndrome, multiple sclerosis, pain that is either chronic and severe or intractable, Parkinson’s disease, positive status for HIV, post-traumatic stress disorder, sickle cell anemia, spasticity, spinal cord disease or injury, terminal illness, Tourette syndrome, traumatic brain injury, and ulcerative colitis[32], and more recently explicitly includes arthritis, chronic migraines, complex regional pain syndrome, Lupus, and degenerative disc disease. Available products include oils, tinctures, plant material, edibles, lotions, creams, and patches. No smoking or combusting of medical cannabis is allowed, though vaporization is permitted. Furthermore, no home cultivation is allowed under the MMCP.
Image: Ohio Medical Marijuana Control Program Logo. Source: Ohio Medical Marijuana Control Program.
Only Ohio residents can register in the MMCP. The first step to become a medical marijuana patient is to establish and maintain a physician-patient relationship with a physician holding an active certificate to recommend (“CTR”) issued by the State Medical Board of Ohio. There are more than 600 qualified physicians[33] and the Medical Board provides a list and interactive map on their website[34] to help patients find a doctor. During the initial appointment, the physician will submit their medical marijuana recommendations for the patient directly into the digital Patient Registry. At this point, the Patient Registry will automatically send an email for the patient to complete their application. The MMCP has partnered with Bamboo Health to provide extensive technical support for patients[35] related to the Registry. The annual registration fee is $50 although veterans and individuals in financial need can have their fees reduced by half[36]. Financial need must be noted during an intake appointment to receive support[37].
To find a licensed dispensary the MMCP maintains a list[38] of operational dispensaries by county on their website and also offer an interactive map. Photo identification is always required to purchase cannabis products. Staff at each dispensary are available for counsel on the appropriate type and dose of product. At this time there is no medical cannabis reciprocity for medical cannabis patients visiting Ohio from other states. It is important to remember that any interstate transport of cannabis remains illegal[39], even for personal medicinal purposes. Limited medical cannabis services may be available to MMCP patients traveling to other areas of the country.
Ohio Medical Marijuana License Applications
After HB 523 became effective in 2016, the Department of Commerce developed an application for cultivators, processors, and testing laboratories as part of the Medical Marijuana Control Program. The licensing process allowed for 12 level I cultivation licenses and 12 level II cultivation licenses, with level I licensees permitted up to 25,000 square feet for cultivation, and level II licensees allowed up to 3,000 square feet designated for cultivation upon initial licensure. In April 2017 applications requirements were released. Level II cultivator applications were accepted June 5-16, 2017 with level I cultivator applications subsequently accepted June 19-30, 2017.
Required information for the application included ownership disclosure, proof of liquid assets (a minimum of $500,000 for level I applicants or $50,000 for level II cultivators), financial responsibility insurance, tax payment records for everyone with more than 1% ownership, business entity form, property owner approval for use as a cannabis business, notice of proper zoning, an organizational chart, a business plan, financial plan, operations plan, quality assurance plan, and a security plan.
109 applications for level I licenses and 76 applications for level II licenses were received by the submission deadline. At the time of licensure award, 15% of the licenses were reserved for social equity applicants. Applications were scored by 25 distinct individuals, including state employees and external consultants. Provisional licenses were awarded in November 2017 to 12 level I cultivators: Buckeye Relief LLC in Eastlake; Grow Ohio Pharmaceuticals LLC; OPC Cultivation LLC; Riviera Creek Holdings LLC; Pure Ohio Wellness LLC; Columbia Care OH LLC; Terradiol Ohio LLC; Standard Wellness Company LLC; AT-CPC of Ohio LLC; Cresco Labs Ohio LLC; Parma Wellness Center LLC; Harvest Grows LLC, and to 12 level II cultivators, Fire Rock LID; FN Group Holdings; Mother Grows Best LLC; OhioGrow LLC; Ancient Roots LLC; Ohio Clean Lead LLF; Ascension Bio Medical; Agri-Med Ohio LLC; Paragon Development Group LLC; Hemma LLC; Galenas LLC; and, Farkas Farms, LLC. The majority of rejected applicants filed to have a hearing to review and challenge the denial. A review by third party consultancy EY[40] found no award changing bias or errors in the originally determined application rankings[41] since PharmaCann, the only impacted applicant, was awarded a license prior to the EY conclusion.
The application acceptance period for processors was December 4-15, 2017. All application materials were required to be hand delivered to the Ohio Department of Commerce office in Columbus before 5pm on the 15th, with both printed and digital copies[42]. The $10,000 application fee was due at the time of application submission. Processors may not own or control more than one license at a given time. Individuals were permitted to submit applications with the same ownership structure for multiple locations with the understanding that they can only accept one license award.
The processor application was broken down into two main sections. Section 1 contained forms provided by the Department for applicants to complete, and section 2 contained prompts to be answered in narrative form within the given page limits. All applicants were required to provide financial disclosures and submit to a background check. Section 1 forms include 1A Business Entity and Contact Information that includes the key information that will be used for filing and tracking purposes; 1B Liquid Assets; 1C Financial Responsibility Form for Insurance; 1D Financial Responsibility Form for Escrow or Surety that certifies the ability to obtain either an escrow or surety bond; 1E Property Owner Approval for Use to show that the applicant is either the owner of the proposed facility property or has a lease or agreement with the property owner that explicitly recognizes and permits the proposed use of the property as a cannabis processor facility; 1F 500 Foot Compliance Cover Page to provide a map that shows the boundaries of the property are more than 500 feet away from the boundaries of any prohibited facility property such as a school; 1G Notice of Proper Zoning to document communication with local zoning officials related to cannabis codes or rules imposed by the local jurisdiction, signed by a local zoning or government representative; 1H Zoning Permit to attach a copy of approved zoning permits; 1I Owners and Officers Roster to list all owners, officers, and direct or indirect operational managers associated with the proposed facility, and any person who has a direct or indirect financial interest in the operation; 1J Organizational Chart with positions of all officers identified in 1I and 1K and other roles as deemed necessary by the business; 1K Individual Tax and Background Information for each person listed on 1I; 1L Business in Other Jurisdictions to disclose information on medical marijuana businesses in other jurisdictions and certify that no owner or officer has received a revocation or suspension from another jurisdiction related to the conduct of cannabis business; 1M Copies of Licenses from Business in Other Jurisdictions; 1N Disadvantaged Group Applicant to certify whether the applicant is a member of a Disadvantaged Group; 1O Entity Identifier Legend if the applicant chooses to redact information regarding identifiable entities affiliated with the applicant in Section 2 of the application; 1P Trade Secret and Infrastructure Record Notification to assert if any part of the application represents trade secrets or record notification; and 1Q Tax Certification Page. Section 2 narratives were crafted without personally identifiable information. Section 2 materials included a 15 page business plan to demonstrate business experience and ability to operate the proposed facility; a 30 page operations plan to detail planned methods of extraction and manufacturing techniques, with related standard operating procedures; a 10 page financial plan and funding analysis to establish the ability to fulfill financial responsibility requirements; a 30 page compliant[43] quality assurance plan; and a 30 page security plan to establish security methods, surveillance technology, emergency notification procedures, and product transportation guidelines, with a plot plan and map that clearly defines restricted access areas.
The Department received 104 applications for processor licenses in the first round. Only 14 applicants initially met all requirements, all of whom were awarded provisional licenses. In October 2018, the Department allowed original applicants that failed the security section to resubmit materials for consideration. The Department achieved their goal of awarding 26 additional licenses after review of the resubmissions, for the regulatorily permitted 40 total processors.
The first testing laboratory applications were accepted in 2017, with a second application round held September 25-November 27, 2020. Both applications included multiple forms for the applicants to complete with relevant business information. Required details included business contact information, disclosure of liquid assets, tax certification, proof of insurance or ability to obtain insurance, proof of escrow or a surety bond of at least $75,000, a financial plan, property owner approval, a 500 foot compliance statement, notice of proper zoning, owners and officers roster, organizational chart, individual tax and background check information, disclosure of medical marijuana businesses in other jurisdictions and copies of licenses if applicable, and a business plan, operations plan, and a security plan[44]. The laboratory application fee is $2,000 and due at time of application, and an initial certificate of operation fee of $18,000. The annual license renewal fee is $20,000. There is no limit to the number of testing licenses that can be awarded by the Department.
Image: North Coast Testing Laboratory. Source: Cincinnati Enquirer.
Dispensary applications were announced on September 17, 2017, with application materials due Nov 3-17. In this initial round 60 dispensary licenses were available, distributed by district. Districts were created by the Board specifically for cannabis dispensary allocation with consideration of population density and access to roadways. The district map was created with consultation from regulators of other states with cannabis programs[45]. The State Board of Pharmacy reserved 15% of licenses in this round for economically disadvantaged groups that identified as such and met the conditions set forth at that time[46]. Individuals can apply for unlimited dispensary licenses but cannot accept more than five dispensary licenses at any time. Operational and provisional licenses are both counted towards this total. Furthermore, no one is permitted to own more than 66% of the dispensaries in a given district[47].
Image: Dispensary District Map. Source: Ohio Board of Pharmacy.
Applications were submitted electronically with a required and nonrefundable fee of $5,000. Required information for the application included a site and facility plan; business startup plan; descriptions of duties for all roles; capital requirements; business history and experience; operations plan; security and surveillance plans; receiving of product operational procedures; storage plans; plan for safe dispensing of products; inventory management plans; plan for diversion prevention; sanitation and safety operational procedures; compliant recordkeeping plans; staff education and training plans; and patient care and education operational procedures[48], all of which were displayed as prompts in the online portal[49] for dispensary applicants. The operations plan accounted for the majority of the application score (52%) and included questions on dispensary oversight; security and surveillance; receiving, storage, dispensing, inventory management, and diversion prevention; sanitation; safety; and recordkeeping[50]. Additional information required for the application included business structure details, disclosure of liquid assets (minimum $250,000 per application), tax authorization, disclosures of criminal background, demographic survey, and declaration of district for the proposed dispensary.
Applications were reviewed by State of Ohio employees including individuals hired specifically by the Board as experts for the purpose of application review. An independent assessment was completed by Gartner Consulting to confirm the integrity of the review process. 56 provisional licenses were awarded; this is four fewer than intended because there were no applicants in Northwest District 2 or Southwest District 3, each with one available license, and there were no qualified applicants from Northwest District 1, with two available licenses. Provisional licensees are granted six months to demonstrate compliance and pass an inspection from the MMCP to obtain a certificate of operation, at which point a $70,000 licensing fee is due.
In April 2021 the Ohio Board of Pharmacy decided to increase the number of dispensary licenses to 130 (from the previous limit of 57). The second dispensary Request for Application was published in September 2021[51]. The application window opened on November 4th and closed on November 18th at 2pm, with all applications and associated fees submitted electronically. Required documentation for the application included the business name and articles of incorporation; proposed facility location with a professional survey and proof of site control; an explicit declaration of the county and district of application; disclosure of ownership in other marijuana entities; an organizational chart and hiring timeline; proof of a surety bond of at least $50,000; criminal background disclosure; a to scale site plan with construction timelines; a detailed budget including projected operational costs and demonstration of liquid assets of at least $250,000; and an operational plan that includes protocols for security, product storage, compliance with state tracking programs, inventory control, operational hours, patient education, and recordkeeping. The Board received more than 1,450 applications[52]. Licenses were awarded based on district.
Current Operators
There are currently 34 medical cannabis cultivators[53], 44 processors[54], 8 testing laboratories, and 114 dispensaries with an active certificate of operation. Additional provisional licenses have been awarded to three cultivators, two processors, two testing laboratories[55], and one dispensary. Provisional dispensary licenses were awarded as recently as March of 2023[56]. The state inventory tracking system (seed-to-sale) is Metrc, and the state prescription monitoring program is the Ohio Automated Rx Reporting System (“OARRS”). Both systems track all sales of medical cannabis products to patients. An interactive map and full list of licensed dispensaries with addresses and contact information can be readily found on the Medical Marijuana Control Program website[57]. No medical cannabis delivery services are currently available[58] but dispensaries with Board approval may provide drive through services[59],[60]. A dispensary can only operate between the hours of 7 a.m.-9 p.m. and must be open for a minimum of 35 hours per week.
Image: Map of Current Dispensaries. Source: Ohio Medical Marijuana Control Program.
Current operators FarmaceuticalRX, Curaleaf (operating in the state as Ohio Grown Therapies), and The Botanist (also known as Acreage Holdings) each contributed financially to the campaign to legalize recreational cannabis in Ohio. Dispensary operator Harvest of Ohio has confirmed they will utilize a dual license to serve medical cannabis patients and the adult use market[61] and Harvest COO Amonica Davis said in a recent CNN interview that “we have a commitment, and are very intentional in creating our workforce that is highly concentrated with women at the executive level. Over 50% of our employees are people of color, and much of our supply chain comes from partners who are traditionally underrepresented in this space[62]”. Other operators have discussed their expansion plans for the recreational market, including vertically integrated Klutch Cannabis of Akron[63], vertically integrated Standard Wellness[64] in Gibsonburg, vertically integrated Ayr Wellness[65] with a new dispensary location in Dayton, and level I cultivator King City Gardens[66].
All medical cannabis operators will be granted a license to partake in the recreational market. Processors, testing laboratories, and dispensaries will be issued adult use licenses of the same type, for use at the currently licensed location. Level I cultivators can expand their canopy area to 100,000 square feet to serve the recreational market, 75,000 more than the current limitation, and will also be awarded three adult use dispensary licenses. Level II cultivators can increase their canopy to 15,000 square feet, a 12,000 square foot expansion, and each will be awarded one adult use dispensary license. Level I or II cultivators may locate their expanded cultivation practices to more than one facility, upon Division approval[67].
Recreational Cannabis
Voters passed “Issue 2” on the November 2023 ballot to legalize recreational cannabis in Ohio. Issue 2 was based on a citizen-initiated petition[68] to the Attorney General of Ohio, which provided draft language for the Act to Control and Regulate Adult Use Cannabis. This became effective law on December 7th. With the law in place, adults in the state can now grow their own cannabis at home safely. Retail sales of adult-use cannabis products will begin in 2024 from currently licensed medical marijuana businesses.
Adult Use Rules
As of December 7th, adults over the age of 21 are allowed to grow up to six plants at their primary residence, with 12 plants permitted for households with multiple adults. Individuals can manually or mechanically process cultivated products at home, but may not process using hydrocarbon-based extraction. All plants must be within a secured room, greenhouse, or other enclosed area that prevents youth access and that cannot be readily seen from a public space[69] such as a sidewalk. Landlords may choose to prohibit cultivation or consumption activities within an individual lease agreement, so each unique situation must be carefully considered. Citizens of Ohio can transfer up to six plants to another consumer, as long as the transaction is free and unadvertised. Elected officials currently seek to reform the adult use rules to prohibit exchange of personally cultivated cannabis[70] and limit the number of plants per household, and they may do so at any future point.
Professional activities related to cannabis are protected and should not result in an immediate revocation of a concealed carry permit or registration revocation by any professional board in the State of Ohio. It is important to note that nothing requires an Ohio employer to permit or accommodate an employee’s use, possession, or distribution of recreational cannabis, even if the action in question is legal statewide. Work or field sobriety tests for cannabis may include breath, urine, or blood samples[71], and cannabis may stay in the body for days or weeks.
Adults can possess up to 2.5 ounces of dried cannabis flower and 15 grams of concentrate. Certain localities[72],[73],[74] have higher possession limits. Cannabis cannot be combusted or vaporized in a vehicle, streetcar, trolley, bike, watercraft, aircraft, or while otherwise in public, and it is illegal for individuals to operate machinery under the influence of adult use cannabis in any form. Mailing cannabis remains illegal in the United States, even between two decriminalized states or within a legal state.
Market Opportunities
The new Division of Cannabis Control is set to create and finalize rules and define the licensing process for new recreational cannabis businesses on or before September 7th, nine months after the law is effective. The statute may undergo further amendments by the state legislature at any time, and amendments could impact the timeline for the rulemaking and licensing process. License types available in Ohio include level I cultivator, level II cultivator, level III cultivator, processor, dispensary, and testing laboratory. All current medical cannabis licencees will receive an adult use license. Every other year after the first adult use operator license is issued, the Division will analyze and report on the current cannabis market, consumer demand, and anticipated market growth to determine if additional requests for application are necessary. Testing laboratory licenses can be awarded at any time and there is no limit to the number of testing licenses available.
Cultivator license levels determine the maximum cultivation space that licensee can use. Level I and II cultivators began in the Medical Marijuana Control Program and now have the option to serve the recreational market as well. Level III cultivator licenses will be awarded for the first time with the inaugural adult use cannabis application. All adult use cultivation licensees can acquire seeds, clones, plants, and other genetic materials for the cultivation of cannabis and may distribute, transfer, and sell cannabis to other adult use cannabis operators. Level I operators are the largest, and post-transition to the adult use market can have up to 100,000 square feet of cultivation space. Post-transition level II cultivators can cultivate in up to 15,000 square feet. Level III cultivator licensees are the smallest operators, with a maximum cultivation area of 5,000 square feet. Independent or vertically integrated processor licenses are available. Cultivators who distribute plant material directly to dispensaries are considered a plant-only processor. Adult use processor licensees can obtain cannabis from other adult use cannabis operators and then manufacture or otherwise process this input into an adult use cannabis product for transfer, distribution, or sale to a licensed adult use cannabis operator. Businesses licensed as testing laboratories may only obtain cannabis from cultivators and processors for testing purposes, and must conduct all testing, research, and operations in accordance with Division rules. Dispensaries may purchase packaged and labeled cannabis from cultivators of any level, processors, or other dispensaries, and may then dispense or sell cannabis and related paraphernalia directly to adult consumers at their retail location or via delivery[75].
Ohio is home to approximately 8 million adults over the age of 21[76], while less than 200,000 individuals are enrolled in the existing medical cannabis program, providing significant market growth opportunity within the state. Purchases from out of state residents are likely to contribute significantly to the new recreational cannabis market as well. Bordering states of Pennsylvania and West Virginia have not yet legalized adult use sales. Citizens of Indiana and Kentucky are notably among the last people nationwide to still lack any access to a medical cannabis program. A few hours away in Virginia, adults can cultivate cannabis at home for personal use, or purchase medical products from an MSO, but there is still no legal mechanism for recreational sales. Interstate transport of cannabis in any amount or form remains illegal, even with the exclusive intent of personal consumption, but visitors to Ohio are likely to regularly partake in the recreational cannabis market.
BDSA, an international cannabis market research firm, predicts that Ohio will be one of the fastest growing legal cannabis markets[77]. Ohio State University recently published a study that estimates annual tax revenue alone from adult use cannabis sales will be at least $276 million after five years of operations, and may broach $400 million. Scioto Analysis, an Ohio based public policy analysis firm, estimates that the legalization of the sale and purchase of cannabis for recreational use will have a net value to the state economy of $260 million per year, in addition to roughly 3,300 new jobs in the first year after legalization[78]. MJBizDaily forecasts adult-use sales could total $1.5 billion to $2 billion in the first year after the market launches and $3.5 billion to $4 billion by the fourth year[79].
Products permitted for sale from licensed recreational dispensaries will include seeds, clones, and live plants, in addition to flower, vapes, extracts, drops, lozenges, oils, tinctures, edibles, patches, beverages, pills, capsules, suppositories, oral pouches, oral strips, inhalers, salves, and lotions[80]. This is a stupendous change from the current medical cannabis market of Ohio, which prohibits flower sales and any combustion.[81] Issue 2 established limits of 35% THC for plant products and 90% for extracts. Adult-use retail products will have a 10% excise tax in addition to sales tax[82]. Taxes will be deposited into an adult use tax fund, then distributed quarterly by the director of the Office of Budget and Management with 36% to the cannabis social equity and jobs fund; 36% to the host community cannabis fund; 25% to the substance abuse and addiction fund; and 3% the division of cannabis control and tax commissioner fund[83]. Current legislation from the Ohio General Assembly may change product potency limits and the distribution of tax revenue.
All currently licensed medical marijuana operators of Ohio will be permitted to operate the same type of license, or more, in the recreational market. For instance, all ten of the current medical marijuana testing laboratories will automatically be given a non-medical cannabis testing license, including provisional licensees[84]. Each current medical dispensary will receive a recreational cannabis dispensary license, and those that are not co-owned by a cultivator or processor will receive two total recreational dispensary licenses. Current level II cultivators will also receive one adult-use dispensary license, and each level I cultivator will receive three dispensary licenses. Current cultivators can increase their canopy square footage once the business is licensed for adult use. This licensure process is set to begin on or before June 7th, 2024 and applications must be reviewed by the Division within three months[85] for award of licenses on or before September 7th. The General Assembly may pass legislation to expedite or prolong this timeline. Sales could begin as soon as licenses are awarded. An open application round for new businesses and interested parties will be available at a later date.
Application Specifics
In the open application round for new adult use cannabis business licenses in Ohio, likely in 2025, there will be 50 dispensary licenses available and 40 level III cultivator licenses. Preference will be given to certified social equity applicants. Social equity participants must verify their status through the Cannabis Social Equity and Jobs Program, which will be established by the Ohio Department of Development prior to the request for application. Application fees for social equity individuals will be reduced by at least half.
All applicants and prospective officers must submit to a background check. Misdemeanors related to cannabis will not be considered disqualifying offenses[86]. The background check will include a confirmation of tax history compliance. No person can have ownership or control of more than one level III cultivation license, and no other adult use cultivators or processors can have any ownership in a level III cultivator license. Additionally, no person can have more than one adult use processor license at any time, and no person can have more than eight adult use dispensary licenses. Further, no cultivator, processor, or dispensary can share any ownership, financial interest, officers, or employees with testing laboratories. The non-exhaustive definition of “person” related to applications and ownership is: an individual; a combination of individuals; a sole proprietorship; a firm, company, joint venture, partnership of any type, joint-stock company, any type of corporation, a corporate subsidiary, a limited liability company, a business trust, or any other business entity or organization; an assignee; a receiver; a trustee in bankruptcy; an unincorporated association, club, society, or other unincorporated entity organization; entities that are disregarded for federal income tax purposes; or any other nongovernmental, artificial, legal entity that is capable of engaging in business.
Anticipated required materials for the application include safety and security plans, cannabis education and training plans, a recordkeeping plan, quality assurance procedures, safety and surveillance plans, testing and tracking plans, an inventory plan, packaging and labeling plan, and a social equity plan[87]. Standard operational procedures may also be requested. All dispensaries must provide training to staff about cannabis addiction services, and related educational materials for all patrons. Applicants will likely be required to have property ownership or control at the time of application. All cannabis business facilities must be at least 500 feet away from any property or parcel operated by a church, public library, public playground, public park, school or preschool, or child care facility – each referred to as prohibited facilities.
Successful applicants will be awarded a provisional license from the Division. Provisional licenses are only valid for three months, and may be renewed for three months with specific Board approval[88]. A certificate of operation will be issued to the provisional licensee after all requirements are met, including an inspection by the Division. Once awarded, operational licenses will be automatically renewed by the Division unless significant cause is otherwise shown.
Conclusion
Advocacy at every level remains crucial for recreational cannabis in Ohio, as legislators actively seek to amend the voter initiated law. There is a strong medical cannabis market in Ohio, which will lead to a large initial recreational market as all current licensees are automatically offered a recreational license. Opportunities for new businesses to enter the recreational cannabis market will be available after the Division of Cannabis Control is established in 2024. Finding a viable location to operate a cannabis business with local approval can be a cutthroat challenge, and interested persons should begin a property search as soon as possible. In addition to careful review of this living document, understanding the statutes, regulations, and ordinances governing the location and activity of cannabis businesses is essential to becoming operational and subsequently maintaining compliance. The process is complex and rapidly changing – contact Cannabis Consultants Group for a consultation.
To win a cannabis license in Virginia, careful preparation and painstaking execution is crucial. This article exhaustively details the political environment, technical license details, general rules and license application requirements, and tips to ensure that your application stands out to regulators and reviewers, giving you the best chance to win a cannabis license in Virginia.
*Editor’s Note: The terms marijuana and cannabis have identical definitions in Virginia, and are used interchangeably. The state regulatory language uses the word marijuana more often, yet a primary governing entity of the program is the Cannabis Control Authority.
History of Cannabis Legalization Efforts in Virginia
1979
Virginia was among the first states in the nation to legalize cannabis for medical purposes. Dr. William Regelson, a professor of medicine at Virginia Commonwealth University, successfully lobbied the state to allow doctors to recommend cannabis for glaucoma, and to treat the side effects of chemotherapeutic agents. Virginia passed legislation in 1979 to protect these uses, based on research carried out by Regelson into the medical properties of tetrahydrocannabinol. Virginia Code 435 § 18.2-251 allowed the possession or distribution of marijuana for medical purposes[1], and protected patients, doctors, and pharmacists from prosecution specifically related to using cannabis in the treatment of glaucoma and cancer.
1998
Unfortunately, Virginia’s state law conflicted with federal law; doctors and pharmacists were federally barred from issuing prescriptions, and with no legal process for patients to obtain medical marijuana, 435 § 18.2-251 and medical cannabis in Virginia languished for nearly 20 years. However, in 1998 the Virginia Senate Committee on Education and Health[2] reaffirmed the use of cannabis in the treatment of glaucoma and cancer. At this time penalties related to personal cultivation of cannabis in Virginia were among the lightest in the nation – presumably as an attempt to permit the sourcing of cannabis for individual patients, considering federal law still banned related prescriptions.
2015
Another 17 years passed before significant movements were made toward legalization of medical cannabis. Then, in 2015, Governor Terry McAuliffe signed two bills[3],[4] that created an affirmative defense for patients using CBD or THCA oils in the treatment of epilepsy, as prescribed by a doctor. These bills did not create a legal method for patients to access medical marijuana. Nevertheless, it was considered a partial win at the time considering the same-year failure by the General Assembly to pass two other bills aimed at decriminalizing cannabis.
2017
Fortunately, the McAuliffe Administration’s wins were sufficient to hasten subsequent legalization advances. In 2017, the Virginia General Assembly passed Senate Bill 1027, the first substantial and specific medical cannabis bill introduced in the state. SB 1027 permitted the cultivation, processing, and dispensing of CBD and THC oils[5] to patients with intractable epilepsy. This bill set the stage for a major shift in policy.
2018
In the subsequent legislative session after SB 1027 was enacted, Virginia HB 1251 was passed, which removed the stipulation that only patients with intractable epilepsy could access medical cannabis oil. This bill allowed doctors to prescribe CBD or THCA oil[6] to anyone with a diagnosed condition that could benefit from cannabis:
“A practitioner may issue a written certification for the use of cannabidiol (“CBD”) oil or THCA oil for the treatment or to alleviate the symptoms of any diagnosed condition or disease determined by the practitioner to benefit from such use.”
As part of this bill, the state Board of Pharmacy licensed five “Pharmaceutical Processors,” which operate as vertically integrated medical cannabis businesses for the cultivation, processing, and dispensing of CBD or THCA oils with up to 5% THC. However, it took nearly two years for these licensees to become operational.
Image: Legalize Virginia Fest September 2018 – VCIA Happy Hour. Source: Virginia Cannabis Industry Association.
2019
The passing of Senate Bill 1557 in 2019 expanded access to medical cannabis in Virginia by allowing physician’s assistants and nurses to prescribe or certify patients and increased the allowable amount of THC in medical cannabis products to 10 milligrams[7].
2020
In February 2020, the Virginia House voted in overwhelming majority to decriminalize personal possession of recreational marijuana, and the state Senate voted similarly on their identical version of the bill in March. The bill was subsequently signed into law by Governor Northam in April and took effect on July 1st, 2020. Under the new law, possession of less than 1 ounce (28 grams) of marijuana is no longer a cause for arrest or criminal prosecution, but a civil offense that carries a $25 fine.
2021
In early February 2021, SB 1406[8] and identical HB 2312[9] each was passed in their respective assembly chambers. Both bills legalized the use and personal cultivation of cannabis at home by any adults over 21. Based on these bills, the Cannabis Control Authority was created and retail sales of adult use cannabis would begin on January 1, 2024. Importantly, certain provisions of the bill do not come into effect unless reenacted by the next General Assembly.
2022
Senate Bill 291 sought to begin retail cannabis sales in September of 2022, but stalled within the General Laws Subcommittee. Legislation from the previous year was not reenacted. Simultaneously, newly elected Governor Glen Youngkin attempted to increase penalties related to certain levels of cannabis possession.
2023
House Bill 1464 was introduced by Delegate Keith Hodges to establish a framework for a recreational retail marijuana market, overseen by the already established Virginia Cannabis Control Authority. House Bill 1750 from Delegate Michael Webert had similar goals, though a different method and timeline. The Committee on General Laws voted immediately to lay both bills on the table, and they will not receive further recognition during this session.
Political Environment for Virginia Cannabis Licensees and Stakeholders
Previous Administration
Terry McAuliffe served as the 72nd Governor of Virginia from 2014 until 2018 and has been a consistent advocate for cannabis legalization. During his tenure as Governor, he signed into law all bills that crossed his desk related to cannabis reform despite voiced hesitancy, including a bill decriminalizing small amounts of cannabis possession and a bill that expanded access to medical marijuana.
Governor McAuliffe was ineligible to run for re-election, which is standard in Virginia, and was succeeded by his Lieutenant Governor, Ralph Northam. Northam won the general election for Virginia Governor with a 9% majority on November 7, 2017[10]. In the 2020 legislative session the assembly passed HB 972 and SB 2 to decriminalize simple marijuana possession[11] and Governor Northam signed the bills into law in May of 2020. The new law states that individuals who possess between one ounce and one pound of cannabis will be subject to a $25 fine and no further criminal proceedings. In February of the following year, the Virginia General Assembly passed a bill introduced by Senator Adam Ebbin to legalize recreational marijuana. However, an important caveat to gain the bipartisan support necessary to pass this bill was that sales could not begin until 2024, and that the subsequent assembly must reenact certain parts of the bill for the market development processes to move forward. Governor Northam insisted that this timeline was not expedient enough, and with the support of the General Assembly accelerated parts of the process by three years, allowing Virginia residents to possess and consume personal marijuana beginning in July of 2021. On April 7, 2021, Northam signed the bill making Virginia the first southern state to legalize adult-use marijuana.
Current Administration
Governor Glenn Younkin was elected in November of 2021 to succeed Governor Northam. At a campaign event he said that he has “never met anybody who habitually used marijuana and was successful”[12] but also stated he would not reverse any cannabis reform that had recently taken place. As Governor-elect he said in an interview with a Virginia based newspaper “I will not seek to overturn the law on personal possession.”[13]
Despite these statements, in April of 2022, Youngkin proposed an amendment[14] that would re-criminalize marijuana possession of over two ounces[15]. Commissioner of the Virginia Department of Agriculture and Consumer Services, Joseph Guthrie, said at a public meeting that “Governor Youngkin has stated that he is not interested in any further moves towards legalization of adult recreational-use marijuana, so I wouldn’t expect that during his administration”[16] in late June of 2023. Governor Youngkin has attempted to gain control over the issue of unregulated delta-8 cannabis products based on the recommendation from a state task force report [17] focused on citizen safety related to these products. After extensive discussion, state lawmakers ultimately approved the Governors amendments; the recreational sale of intoxicating hemp-derived products is now banned in Virginia[18].
The Senate and Assembly have proposed multiple bipartisan bills since 2021 related to establishing a framework for creation of a recreational marijuana retail market, but without success. In the 2023 session Republican Delegate Hodges introduced HB 1464[19] with this goal, and the end result was a subcommittee determination to pause further progress. All 100 seats of the House of Delegates and all 40 seats in the Senate of Virginia are up for election this November, in the first statewide election since intensive electoral redistricting.
Cannabis Regulatory Bodies
There are four governing bodies relating to cannabis in the state of Virginia: the Board of Pharmacy, the Cannabis Control Authority, the Cannabis Public Health Advisory Council, and the Cannabis Equity Reinvestment Board.
The Board of Pharmacy is a health regulatory board within the Department of Health Professions that licenses pharmacists, pharmacy technicians, and pharmaceutical processors, and regulates the practice of pharmacy and the manufacturing, dispensing, selling, distributing, processing, compounding, or disposal of drugs and devices for the safety of patients in the Commonwealth of Virginia. In August of 2017, the Board of Pharmacy adopted emergency regulations[20] establishing health and safety oversight of medical cannabis. They then oversaw the launch and inaugural years of the statewide medical marijuana program. The Board of Pharmacy consists of ten members and one executive director, including two citizen members and eight licensed pharmacists[21]. All members serve for staggered four year terms, and the Board elects a Chairperson each year from its pharmacist members; subsequent membership terms are allowed. The current Chairman is R. Dale St. Clair, Jr., PharmD, and additional members include Cheryl L Garvin, Ling Yuan, Wendy C. Nash, Shannon Dowdy, Sarah Melton, Kristopher S. Ratliff, and Patricia Lynn Richards-Spruill, all licensed pharmacists, and S. Lawrence Kocot as the sole citizen member, with one Board vacancy. The Executive Director for the Virginia Board of Pharmacy is Caroline D. Juran who has acted in this role since 2010, directly after serving for five years as the Deputy Executive Director.
Image: Board of Pharmacy Logo. Source: Virginia Department of Health Professions.
The Cannabis Control Act of 2021 created the Cannabis Control Authority (“CCA” or “Authority”). The Act empowers the CCA to undertake initiatives and promulgate regulations on various public safety and public health aspects of cannabis. Oversight of the medical cannabis program will fully transition to the CCA on January 1, 2024. The CCA is composed of a five member Board of Directors, a leadership team, and additional support staff. The current Board Chair is John F. Keohane, retired and esteemed Police Chief of Hopewell City, who was appointed to the position by Governor Youngkin in August of 2022[22]. Prior to this, Neil Amin served as Board Chair since appointment by Governor Northam in July of 2021[23]; Amin is a life-long Virginia resident, has previously served on the Virginia Treasury Board, Virginia Small Business Financing Authority, and the Governor’s Advisory Council on Revenue Estimates, and is now vice-chair of the CCA board. Additional board members include Bette Brand, Michael Jerome Massie, Esq., and Anthony D. Williams. Brand has served in several roles at the United States Department of Agriculture. Massie is the former CCA vice-chair, and is a trial lawyer with experience at every level of Virginia’s courts and federal courts. Williams is the newest board member, appointed to his position effective July 1st 2023[24] by Governor Youngkin. Williams is a former Special Agent in Charge and Chief of Operations for the US Drug Enforcement Administration, with more than a decade of leadership within the DEA including significant experience with cannabis related operations. The CCA leadership team includes Jeremy Preiss as acting Head and Chief Officer – Regulatory, Policy and External Affairs; Jamie Patten, Chief Administrative Officer; and Shawn Casey, Director of Regulation and Policy. The CCA and CCA Board hold public meetings on a regular basis, at least once per quarter. The CCA has created more than a dozen publicly available resources[25] related to cannabis health and safety, including documents for responsible adult use of cannabis, a “parent toolkit” focused on youth cannabis use prevention, and safe home cultivation methods for adults.
Image: Virginia Cannabis Control Authority Logo. Source: Virginia Cannabis Control Authority.
The Cannabis Public Health Advisory Council (“CPHAC”) is an advisory council to the CCA Board of Directors. The purpose of the Advisory Council is to assess and monitor public health issues, trends, and impacts related to marijuana and marijuana legalization, and to make recommendations regarding health warnings, retail marijuana product safety, product composition, and public health awareness, programming, and related resource needs[26]. Members of the advisory council are appointed by the Governor and General Assembly, and the Commonwealth Secretary of Health and Human Resources chairs the group. The CPHAC has 21 members, who include cannabis business professionals, medical doctors, academic cannabis researchers, a registered medical cannabis patient, and a citizen representative of a local health district; the current CPHAC Chair is John Littel, who has over three decades of public policy expertise[27].
The Cannabis Equity Reinvestment Board (“CERB”) is a policy board within the executive branch of the Virginia government. The mission of CERB is to support people, families, and communities historically and disproportionately targeted and affected by drug enforcement. Select methods include development and implementation of scholarship programs, educational programs, and vocational resources for historically marginalized persons, who have been adversely impacted by substance use individually, in their families, or in their communities, including persons in foster care. The CERB will develop and implement a program to award grants to support cannabis workforce development programs, mentoring programs, job training and placement services, apprenticeships, and reentry services that serve persons and communities historically and disproportionately targeted by drug enforcement, and the board will administer the Cannabis Equity Reinvestment Fund. The CERB works closely with the CCA and the Virginia Office of Diversity, Opportunity, and Inclusion for support with program implementation and to provide policy recommendations in line with the CERB purpose. The CERB has 20 members, including 13 citizen members and seven ex-officio members. Citizen members are appointed by the Virginia Senate Committee on Rules, Virginia Speaker of the House of Delegates, and by the Governor, based on regulatory criteria such as professional area of expertise[28]. Ex-officio members of the Board serve terms concurrently with their terms of office – these specifically include the Virginia Secretary of Education; Secretary of Health and Human Resources; Secretary of Public Safety and Homeland Security; the Director of Diversity, Equity, and Inclusion; the Chief Workforce Development Advisor; the Attorney General; and the Chief Executive Officer of the CCA, although the CCA CEO does not have CERB voting privileges.
Virginia Medical Cannabis Licenses
Regulations
Medical cannabis has been legal in the Commonwealth of Virginia since 1979. However, licenses for the cultivation, processing, and dispensing of cannabis oils to medical cannabis patients were not written into regulations until 2017 with Senate Bill 1027[29]. This legislation determined that licenses for “pharmaceutical processors” should be distributed by health region, also referred to as health service area (“HSA”), with one license available per region[30], and that the application and award process should be overseen by the Board of Pharmacy. A pharmaceutical processor of Virginia is a vertically integrated medical cannabis business that is permitted to cultivate, process, and dispense medical cannabis[31] to patients that have received a written certification from a registered practitioner for treatment. There are five HSAs[32] in the Commonwealth, as defined by the Board of Health.
Image: Map of Health Districts and Health Service Areas in the Commonwealth of Virginia. Source: Virginia Board of Health and Virginia Division of Health Statistics
The Board of Pharmacy created emergency regulations for the safe and effective governing of medical cannabis pharmaceutical processors, effective from August 7, 2017 until February 6, 2019. The current regulations, effective since August 2023, can be found on the Board of Pharmacy website[33]. On January 1, 2024, oversight of the medical cannabis program will shift to the CCA; staff from the Board of Pharmacy and Cannabis Control Authority have closely and extensively analyzed this matter, and received counsel from the Office of the Attorney General related to change management. The Board of Pharmacy plans[34] to repeal their regulations effective January 1; the CCA published draft regulations[35] related to medical cannabis on September 7, 2023, in which much of the terminology and language is adopted directly from the current Board of Pharmacy regulations. The CCA regulations are intended to go into effect on January 1.
Each pharmaceutical processor may have up to six dispensary locations, the first of which must be co-located with their cultivation and processing operation. Each dispensary location must have a Pharmacist in Charge on site responsible for the oversight of medicinal cannabis dispersal to qualified patients, with licensed pharmacist technicians available to assist in this process. Allowable products for sale in the Commonwealth include tinctures, lotions, edibles, nasal sprays, suppositories[36], vape cartridges, and flower. New products must be tested and submitted to the governing entity for review and approval. There is no cap on total THC levels, however, no single dose of a product can contain more than 10 milligrams of THC. Each product must be tested by a third-party lab and an analysis report must be provided before the product can be dispensed.
Original Applications
The application process for pharmaceutical processor permits has three stages: submission of initial application, award of conditional approval, followed by finalization of a pharmaceutical processor permit. Applications for licenses were first accepted by the Board of Pharmacy on April 16, 2018. The required information for each 2018 pharmaceutical processor application[37] included a detailed analysis of the applicant’s financial position and experience within the cannabis industry generally; disclosure of all owners and their written agreement to complete a criminal background check; narrative explanation of cannabis cultivation or other professional agricultural experience; the proposed locations of business, hours of operation, and anticipated commencement date; safety and security plans for inventory, personnel, and the premises; delivery plans that mitigate diversion risk; marketing plans; a compassionate need plan to support low income medical cannabis patients; a cannabis specific scientific research plan; and a confirmation that the applicant is allowed to conduct business within the Commonwealth. Additional forms provided by the Board and a $10,000 non-refundable fee was also required for an application to be considered complete.
The Board of Pharmacy received 51 complete applications by the June 8, 2018, 2 pm deadline. A closed committee reviewed and scored all applicants, and then submitted to the Board of Pharmacy recommendations for conditional license approval. Conditional licenses were awarded in the winter of 2018 to PharmaCann in HSA I, Dalitso in HSA II, Dharma Pharmaceuticals in HSA III, Green Leaf Medical in HSA IV, and Columbia Care in HSA V. After a multitude of mergers and acquisitions, some successful and others failed, along with a suite of related lawsuits and appeals, there have been significant changes of control in the majority of the health regions. Regulatory limits of one pharmaceutical processor per region still stands, although since 2020 each licensee may have up to five additional off-site medical cannabis dispensaries within their HSA.
Current Operators
HSA I currently has no licensed or conditional operator. PharmaCann sold their conditional license to MedMen for $10 in December 2019, as part of a terminated business merger. Ultimately, neither of the relevant parties in HSA I put forth effort towards the development of the pre-approved pharmaceutical processor property in the allotted one year timeframe, nor did they communicate effectively with the town council or with the Board of Pharmacy about this lack of development, which resulted in a revocation of the HSA I conditional license in June 2020.
The Board of Pharmacy accepted new applications specific to HSA I in September 2020, with an anticipated[38] conditional approval by March of 2021, and 26 completed applications were received. However, related lawsuits from PharmaCann filed that same month in Henrico County paused the process for years. The Virginia Court of Appeals ruled in favor of the Board of Pharmacy in April 2023, finally allowing forward progress related to the 2020 application round. On July 6, 2023, the Board of Pharmacy issued a formal notification all HSA I active applicants that the Board may rescind the 2020 application, since oversight of the medical cannabis program will shift to the Cannabis Control Authority in January and the remaining calendar year would not provide enough time for a fair and complete evaluation of applications based on guidance from the Attorney General’s Office. On September 26th 2023, three years after initial request, the Board voted unanimously[39] to rescind the HSA I application, and encourages all parties interested in a pharmaceutical processor license to engage with the CCA process in 2024; all 2020 applicants will receive an application fee refund.
HSA II is controlled by Jushi Holdings, a publicly traded hemp and cannabis operator with more than 30 cannabis dispensaries across seven US states[40]. The international company gained majority control[41] of Virginia-based Dalitso in 2019, when Jushi paid $16 million to acquire 62% ownership of Dalitso. In December of 2020, Jushi purchased the last remaining stocks[42] of Dalitso for $22 million, resulting in Jushi’s 100% ownership control within the HSA II region. Also in December of 2020, the first medical dispensary in HSA II commenced operation[43] doing business as Beyond / Hello. The Beyond / Hello brand originated in Pennsylvania[44] before acquisition by Jushi in July 2019[45]. There are currently six licensed medical cannabis dispensaries[46] in HSA II, including a new location in Woodbridge that opened in August 2023.
Virginia-based Dharma Pharmaceuticals was the first licensee to commence retail operations in the Commonwealth, in HSA III, and opened their Bristol mall location[47] to registered patients on October 17th, 2020. Less than a year later, Dharma was forced to transition away from this location and instead to nearby Abingdon, when Hard Rock Hotel purchased the Bristol mall property to build a casino. Then, in May 2021 Green Thumb Industries announced an agreement[48] for 100% ownership acquisition of Dharma Pharmaceuticals for $80 million[49]. Green Thumb Industries is a national cannabis company that currently owns and operates 79 dispensary locations[50] under various names across 15 U.S. markets, plus a suite of seven cannabis brands, with all of their dispensaries operating under the “RISE” brand name. HSA III now has six[51] RISE medical cannabis dispensaries, the most recent of which opened[52] on June 28th in Danville, coincidentally down the street from our Cannabis Consultants Group headquarters.
Image: Interior of RISE Danville Dispensary. Source: RISE Medical Marijuana Dispensary Danville August 2023.
The remaining two health regions, HSA IV and V, are both now operated exclusively by The Cannabist Company – formerly known as Columbia Care, LLC. Columbia Care, based in New York and with licensed dispensaries in Arizona, Massachusetts, New York, Illinois, Washington, D.C., California, Delaware, Puerto Rico, Pennsylvania, Maryland and Florida, was the original awardee[53] of the HSA V conditional license in 2018. Columbia Care opened their first Virginia dispensary location in December 2020[54] in the town of Portsmouth, and an additional five retail locations in the region since then, with the most recent in Suffolk which opened on August 2nd, 2023. The HSA V region now has the maximum allowable six dispensaries, all operating under the company name Cannabist[55]. As of September 21, 2023, Columbia Care has changed its legal operational name[56] to The Cannabist Company. Green Leaf Medical, commonly referred to as gLeaf, was awarded a conditional license in 2018 from the Board of Pharmacy to operate as a pharmaceutical processor in HSA IV, and received final operational approval on May 12, 2020[57]. Green Leaf Medical immediately commenced cultivation operations, quickly becoming the largest cultivator in the state, and then opened their Richmond, Virginia location to medical cannabis patients in the late fall of 2020[58]. Mere months later, in December of 2020, Green Leaf agreed to be acquired[59] by Columbia Care for $240 million in cash and stocks; the transaction was completed[60] in June 2021. The acquisition included the gLeaf operational vertically integrated facility in Richmond, their regional pharmaceutical processor license of Virginia, and their active licenses in the competitive cannabis markets of Maryland, Ohio, and Pennsylvania. As part of the merger agreement, the entire Green Leaf management team was retained through the merger, and the gLeaf CEO was instated as a voting Director on the Columbia Care board. Additional dispensaries in HSA IV did not start to open until November 2021, with a Columbia Care (now The Cannabist Company) owned location in Glen Allen, branded as gLeaf. The newest regional dispensary in Colonial Heights is also branded as gLeaf, although the Carytown location[61] that opened in October 2022 does business as Cannabist. Up to two more medical cannabis dispensary locations can be added in HSA IV.
Future Applications
Applications for pharmaceutical processors in Virginia are not currently being accepted by any entity, and no upcoming application rounds have technically been announced. Auspiciously, the Cannabis Control Authority has stated that they plan to request applications in early 2024[62], exclusively for the HSA I vacancy. The CCA has released draft regulations[63] for the oversight and regulation of pharmaceutical processors, including information about license applications, with an effective date of January 1.
When the CCA opens applications for pharmaceutical processor licenses, the required information will likely include the name and address of the applicant and all owners; criminal background checks; expansive details of the applicant’s financial position including assets, liabilities, income, net worth, and as needed evidence of an escrow account, letters of credit, or performance surety bond; documents of proof that the applicant is permitted to do business in Virginia, such as State Corporation Commission registration or similar; disclosure of any previous medical cannabis application in any state, and the outcome therein, including any related disciplinary actions, as well as disclosure of any previous or current involvement in the medical cannabis industry. Documentation of business practices and organizational intent will also likely be required, including an organizational chart; plans for the safe dispersal of medical cannabis; marketing plans; details of compassionate need programs that the business will offer; an odor mitigation plan; a waste management plan; and a multitude of additional operational plans.
Each applicant must have a location selected prior to submission within the specified HSA, with text and graphic materials showing the exterior appearance of the proposed pharmaceutical processor; documentation that all state and local building, fire, and zoning requirements and local ordinances will be met prior to operational commencement; a facility safety and security plan; and a blueprint of the facility that explicitly shows the square footage of each area of the facility, the location of all safes intended to store cannabis, location of all areas that may contain cannabis, walls, counters, and all points of ingress and egress. The property must be at least 1,000 feet away from a school or daycare, and additional locality restrictions may be applicable.
The anticipated fees for pharmaceutical processors are $18,000 to apply and $165,000 for an initial permit, then an annual permit renewal fee of $132,000; location changes, remodels, acquisitions, or expansions are subject to a $5,000 fee. A separate application for each cannabis dispensing facility (up to five) or cultivation facility (one) permit shall be submitted to the board, with a predicted application fee of $5,000 and an initial permit fee of $80,000 per location. Additional fees apply for changes to the business name, changes of ownership, for each reinspection, and a $50 fee for the registration of each cannabis product with the CCA. All fees are non-refundable.
The application process for pharmaceutical processor permits will remain the same as previous application rounds, with three stages[64] including a submission of initial application, then an award of conditional approval, and a final issuance of a pharmaceutical processor permit after all inspections and other requirements are completed. A notice of open applications will be published by the CAB[65] and will include specific details on how to obtain and complete an application, the deadline, required fees, and criteria of scoring. Interestingly, the regulations do not provide details on how long the application window will be, nor if there will be any advance notice given. The CAB also reserves the right to change the notice of open applications at any point prior to the deadline for submitting an application.
Medical Cannabis Patients
After decades with no legal pathways to access medical cannabis – despite laws and strong agreement that cannabis is, in fact, medicine – there have now been 55,000[66] medical cannabis patients registered in Virginia, representing around 0.5% of the citizens. This is a significantly smaller percentage of registrants than in other medical-only cannabis states[67], with a national average around 2%. More patients do register with the Virginia program each week, however many citizens of the Commonwealth are unable to access the program due to high fees of registration and exorbitant product prices. For months there were also delays in response to medical cannabis patient registration applications, further exacerbating the issue. In response to this, the Virginia General Assembly passed HB933, which removes the requirements[68] for medical cannabis patients to register with the Board of Pharmacy, and instead allows patients to access products once they have approval and a written recommendation from a registered practitioner for medical cannabis, effective July 2022 and signed by Governor Youngkin. This legislation does not impact the need for all physicians to register with the Board of Pharmacy as a registered practitioner of cannabis oils in order to recommend medical cannabis to patients and obtain CMEs specific to medical cannabis for annual registration renewal; these recommendations are notably different from prescriptions, as legal prescriptions must be on a specific DEA authorized[69] prescription pad. Given the legislative change, it is accepted that the number of active medical cannabis patients has already exceeded the number registered with the Board of Pharmacy, and it is anticipated that the number of patient registrations will stagnate and then drop. Citizens of the Commonwealth that wish to partake in the medical cannabis program can find a list of registered practitioners on the Board of Pharmacy website[70] to conduct a medical consultation.
Image: Becoming a Medical Cannabis Program Patient. Source: Virginia Cannabis Control Authority
Although there is not a current mechanism to achieve an accurate patient count, the expectation is that overall patient numbers will rapidly increase with one less burdensome step prior to medical cannabis access. All patients still have the option to receive a physical medical cannabis card and may register with the Board of Pharmacy to receive one. Importantly, a physical card may be required by other states for reciprocity in their medical cannabis program. For example: Virginia dispensaries never provide medical cannabis to patients from outside the Commonwealth, but directly next door, the District of Columbia allows access to medical cannabis patients from any jurisdiction, with appropriate identification, and now even allows Virginia qualified patients to access products without a Board of Pharmacy registration card.
Virginia Recreational Cannabis Licenses
Regulations
Originally passed in 2021, Virginia bill 2312[71] says retail sales of recreational marijuana can begin on January 1, 2024. Unfortunately, that will not be happening, due to changes in the political environment and the lack of 2022 legislative reenactment on critical sections of the bill. There have been several bills put forth since then in both the Senate and House to establish a framework for a retail recreational cannabis market in Virginia overseen by the currently established CCA, but all related bills have stalled under bi-partisan committee review. The CAB may not promulgate rules or regulations for the recreational cannabis market until a legislative framework is approved[72] by the General Assembly.
The process to create regulations would include internal drafting of regulations by the CCA and CAB, a public notification of proposed regulations and a public comment period, potential redrafting, and then regulatory adoption[73] dependent on session timing. Internal regulation drafts will likely be produced quickly, given the public pressure and long wait for recreational cannabis, the multiple and extensive drafts already created within the General Assembly, the depth of detail provided in the Virginia Cannabis Control Act, and the active medical cannabis regulations of Virginia. However, some state entities have taken years to draft initial regulations, even when statutorily obligated to do so sooner. The CPHAC will coordinate with the CAB to establish social equity guidelines before the application period begins. Public comment periods must be at least 30 days[74] in the Commonwealth, and there may be multiple rounds of public comment if drafted regulations undergo significant changes to accommodate public feedback. Local jurisdictions are likely to create additional ordinances specific to cannabis businesses, and may vote by ballot to prohibit retail dispensaries completely.
Adult Use Market
Currently, adults in the Commonwealth are permitted to cultivate up to four secured cannabis plants per household for personal use, can gift or share up to one ounce with friends, and can possess (not consume[75]) up to one ounce in public. Public possession of more than one ounce of cannabis but less than four ounces may result in a civil violation, while an intent to distribute the same amount[76] is considered a felony. When cultivating at home, each plant must be secured and have a tag on it with the owners name, drivers license number, and a legible note that the plant is grown for personal use only[77]. There is technically no legal method in which to purchase a starter mother plant or seeds without a recreational retail market; notable large-scale seed giveaways in the Commonwealth have taken place, including events from Veterans Initiative 22[78] and Virginia Marijuana Justice[79] on July 1st 2021 when home cultivation first became legal, and multiple recurring and spontaneous events[80] from Peninsula Hydroponics (“pH”), a small locally owned business; Peninsula Hydroponics will host their final seed giveaway of 2023 on November 24th.
Hemp derived THC currently dominates the Virginia recreational cannabis retail market, often sold in smoke shops or gas stations. These products often do not conform to marketing or testing regulations, though many are tested. Legislators approved a bill that Governor Youngkin proposed[81] to ban intoxicating hemp based products[82], with CBD:THC ratios of 25:1 still allowed. The new regulations went into effect on July 1, 2023[83] and the state immediately began to issue related fines and citations[84]. On September 1st, multiple hemp business owners along with one hemp customer filed a lawsuit against the state arguing irreparable harm will be caused by the hemp prohibitions; their case is scheduled to be heard on September 29th in the District Court of Alexandria.
Recreational Cannabis Applications
The timeline for the CCA to accept recreational cannabis license applications includes a months-long process after legislative progress is enacted, which is unlikely until at least 2024. This process will include the creation of regulations and the related public comment period before an application period is announced. In many states advance notice is required from the regulating body prior to any cannabis application period to give interested parties enough time to understand what is needed; for example, neighboring Maryland is required to give 60 days[85] advance notice. However, the Virginia Board of Pharmacy notably accepted applications for pharmaceutical processors on the same day as their original request for application announcement , with all completed applications due 72 days later. This could also happen with the CCA applications for recreational cannabis licenses.
Some states have chosen to allow currently licensed medical cannabis operators a transitional license to also serve the recreational retail market before a general application period is made available to the public. Original regulatory language from house bill 2312 explicitly states this will not be the case in Virginia, and instead describes an initial application round with priority given to social equity applicants. A 2022 Senate bill sought to change that fact, and would instead permit currently licensed pharmaceutical processors and industrial hemp processors to sell recreational retail products with a one time fee of $1 million. While this specific bill did not pass, it showcases the lack of clear guidance from the legislature, and predicts that the rollout of recreational cannabis licenses could still change significantly.
The application itself is likely to require ownership disclosures; business incorporation documentation; organizational structure information; and, proof of financial responsibility through account documentation, tax history, letters of support, and financial projections. Interestingly, police officers with police authority in the political subdivision of the future business are prohibited from submitting a recreational cannabis license application in that jurisdiction; additionally, a manufacturer, distributor, or retailer of alcoholic beverages, or a retailer of tobacco or tobacco products, may not apply for a recreational cannabis license. If any of the aforementioned individuals are on your application, it will be rejected. Details about the proposed business location; security and safety plans; product testing plans; and inventory tracking plans will likely also be needed for the application. Proposed locations must be specifically identified, but the applicant is not required to have control over the premises in their initial application. All properties must be located in a way that will not adversely affect any residence or residential area; place of religious worship; hospital; public, private, or parochial school or institution of higher education; public or private playground or other similar recreational facility; substance use disorder treatment facility; or federal, state, or local government-operated facility. All retail dispensaries must be at least 1,000 feet away from existing retail dispensaries.
License Types
The Virginia Cannabis Control Act defines license types and sets limits for each category. Permitted businesses will include cultivation, manufacturing, and retail facilities, as well as wholesaler licenses. The maximum allowable permits will be 450 cultivators, 60 manufactures, 25 wholesalers, and 400 retail dispensaries. Licenses are likely to be distributed systematically based on region and community, to avoid certain areas with an oversaturation of dispensaries. Applicants are limited to one license type[86], except for current hemp operators, who can pay a fee of $1 million to conduct vertically integrated business.
Cultivation licenses are further defined by two classes: class A licensees are authorized to cultivate up to a set number of marijuana plants and up to a set canopy square footage, with numbers determined by the CAB at a later date; class B[87] licensees can only cultivate cannabis with 1% THC or less, post-decarboxylation. Manufacturer licensees can sell products to other manufacturers or to wholesalers, but not directly to retailers. Wholesalers can purchase cannabis from licensed cultivators, manufacturers, or other wholesalers, and then sell or resell it to licensed retail operators. Retailers can only purchase from wholesalers, and can only sell to consumers over the age of 21 with valid identification. Each customer sale at licensed dispensaries must be conducted in person by a human – drive through sales, automated dispensing machine sales, vending machine sales, internet sales, and delivery services of recreational cannabis are all explicitly prohibited[88] for recreational cannabis in Virginia.
Conclusion
There are still many necessary steps for the legislature and other entities to take before an application for recreational cannabis licenses in Virginia will be available. The current political environment is far from ideal for cannabis progress, although all 140 General Assembly seats in the Commonwealth are up for election this year. Changes to the regulatory bodies that oversee cannabis businesses in Virginia will be final in January. The medical cannabis market still lacks a region I provider, and costs are extremely high across the Commonwealth for medical cannabis products. Pharmaceutical processor applications will likely be available in early 2024, and interested individuals should start preparing now. Cannabis Consultants Group will continue to track relevant bills, attend every CCA and CAB meeting, and update this living article accordingly to keep you prepared for the upcoming applications.